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Chapter 1 
Introduction 
Stress urinary incontinence (SUI) is a common and potentially debilitating problem. It can 
affect physical, social and physiological functioning and health perception, as well as in some 
cases sexual function, participation in employment and sleep (1,2). The prevalence of SUI 
increases with age and tends to be higher in women, older people and an institutionalized 
population (3). In different older and more recent studies the prevalence varies considerably 
(8 – 43%). This could be due to different definitions of SUI, design of the questionnaires, 
study population and selection criteria (4-8). Proportions of types of urinary incontinence 
(stress, urge and mixed) are difficult to estimate, and estimates vary considerably. 
Approximately half of all incontinent women are classified as stress incontinent (8). A recent 
study by Hannestad et al which included the entire age range demonstrates a decrease in 
prevalence of SUI from 40-49 year old age group through the 60-69 year old group (9). 
Another issue is the possible under-estimation of SUI due to underreporting and consequent 
under-diagnosis, as urinary incontinence is often considered to be an inevitable part of aging, 
and an embarrassing and untreatable condition (10,11). In a recent survey (2004) performed 
in 4 European countries, it was reported that 60-76% of women had not consulted a physician 
for urinary incontinence (UI). About 50% of women with UI used pads and 2.1% have had a 
surgical procedure for their condition (12).   
In 2002 the International Continence Society (ICS) reported definitions of symptoms, signs, 
urodynamic observations and conditions associated with lower urinary tract dysfunction and 
urodynamic studies (13). SUI as a symptom is the complaint of involuntary leakage on effort 
or exertion, or on sneezing or coughing. SUI as a sign is the observation of involuntary 
leakage from the urethra, synchronous with exertion/effort, or sneezing or coughing. The 
urodynamic observation of stress urinary incontinence is the involuntary leakage of urine 
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when the intra-vesical pressure exceeds the urethral resistance as a result of increased intra-
abdominal pressure in the absence of a detrusor contraction (13). 
A healthy, functioning striated sphincter, a well-vascularized urethral mucosa and 
submucosa, a properly aligned and functioning intrinsic urethral smooth muscle, and an intact 
vaginal wall support are necessary for the urethra to remain closed at rest and during 
increased abdominal pressure for preventing SUI. These factors are well characterized, but 
their functional inter-relationships are still not fully understood (14).  
The pathophysiological concept of SUI is conventionally considered as a dichotomy, due to 
either urethral hypermobility (displacement, or prolapse of the vaginal wall) or intrinsic 
sphincter deficiency (ISD). Currently, there appears to be a shift away from this simple 
categorization to a continuum between both categories. This has arisen in part because of the 
development of the concept of Valsalva Leak Point Pressure (VLPP) and more recent 
analyses of long-term results of stress incontinence surgery. These results of correction of 
hypermobility have suggested that there may be more urethral weakness among patients with 
urethral hypermobility than had been previously considered (14). 
Treatments for SUI include lifestyle modifications (losing weight, quitting smoking, 
regulating fluid intake), pelvic floor muscle training (PFMT), minimally invasive devices, 
pharmacotherapy, urethral injection and surgery (See flowchart from ICI 2005). Patient’s and 
physician’s preferences, co-existent problems, physical features of the patient affected and 
evidence of treatment often influence the choice of treatment. It seems logic that in the 
treatment algorithm of SUI, PFMT is first choice before further interventions for SUI (15). 
Several randomised controlled trials (RCTs) have demonstrated that PFMT is more effective 
than no treatment for SUI as described by Bø et al (16) and Hay-Smith and Dumoulin (17). 
Subjective cure/improvement rates of PFMT reported in RCTs vary between 56 and 70% 
(16). Cure rates defined as < 2 grams of leakage on different pad tests vary between 44 and 
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69% (16). Compared to surgery, PFMT has no known side effects, is relatively inexpensive, 
and women should be motivated to intensively perform PMFT as first line treatment (16). 
However, long-term success depends on compliance, adherence to therapy and how 
disciplined the woman is in continuing the exercises and on the availability of a skilled 
physiotherapist (18). If PFMT is not successful, the next option could be invasive therapy 
(See flowchart from ICI 2005). In general, surgery has been widely considered as the only 
effective treatment after conservative therapy (27). However, surgery is not suitable for all 
patients, and fear of complications may act as an obstacle (19). An alternative option is 
injection therapy with urethral bulking agents (UBA’s) and is generally considered as a 
minimally invasive procedure for SUI (20-22). “Minimally invasive” is a relative term and 
can be viewed as minimally invasive from physician’s or patient’s perspective. Acceptance of 
injection therapy as the least invasive of all invasive procedures is progressing (20-22). 
Injection therapy is suggested to offer several potential advantages over other surgical 
procedures, including lower morbidity, shorter procedure time, shorter inpatient stay and 
more rapid recovery (19,23). The procedure is most commonly based on day-case care and 
use of local or regional anesthesia.  
In general, the outcome of treatment for SUI is often unsatisfactory. This reflects uncertainty 
about which of the available treatment options are the most appropriate and effective, which 
may in part be due to lack of standardization of diagnostic criteria and outcome parameters in 
studies investigating this issue (24,25). The wide variety of surgical treatments for SUI 
indicates the lack of consensus as to which procedure is the best. Evidence based guidelines 
using the available literature have been published but were based on studies of moderate 
quality and type (26-29). Therefore, there is a growing need to justify the rationale for 
treatments, and to provide evidence that a treatment such as injection therapy does have 
effect on SUI and impact on patient’s condition (26).  
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In fact, the situation is similar for injection therapy with UBA’s. Many UBA’s have been 
developed, although the ideal one remains to be discovered (19,30). Safety profile and 
durability of these agents remain a concern (19,30). Different injection techniques of UBA’s, 
endoscopic and non-endoscopic administration, have been used. Injection therapy can be 
offered for all types of SUI as will be discussed in chapter 2. UBA’s were usually used for 
ISD related SUI, although there is good evidence that women with (concomitant) urethral 
hypermobility respond similarly (31).  
The exact place of injection therapy in a treatment algorithm of SUI is still unknown.  In a 
recent Cochrane systematic review (2007), the effectiveness of periurethral/transurethral 
injection therapy for urinary incontinence in women has been reviewed (32). The authors 
reported that paucity of published data made pooled statistical analysis inappropriate and 
prevented meta-analysis.  However, data suggested subjective and objective short-term 
improvement of SUI in women. It was also noted that the transurethral route results in fewer 
complications compared with periurethral injection (less retention and urinary tract 
infection). No studies were found comparing injection therapy with pelvic floor muscle 
training. Two studies that compared injection therapy with surgical management (bladder-
neck suspension, Burch colposuspension, and pubovaginal sling) found statistically 
significant better objective outcome in the surgical group (33,34). Although no statistical 
significant difference in subjective outcome was reported between these groups.  The 
complications (complete retention, transient difficult voiding, and urinary infection) were 
statistically significant more frequent in the surgery group.  
In recent years, several suburethral tapes have reduced drawbacks (impact on hospitalization 
and convalescence, harvesting fascial sling) of other surgical suspension techniques. These 
tapes seem to result in high cure rates (84-95%) and remain stable over time, with a reported 
85% of patients cured and 11% with significant improvements after 5 years (35-37). 
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Although the adverse events of tapes are still substantial and can have a serious impact on 
quality of life, such as bladder perforation (0.5-14%), voiding difficulties (1.4-15%), vaginal 
erosion (0.7-33%), urethral erosion (2.7-33%), de novo urgency (7.2-25%) (38). Voiding 
difficulties, such as weak stream and retention, can persist in the long term (3½ years; 39). 
Also sexual impairment including dyspareunia and loss of libido can occur (40). Even seven 
deaths after the first 500000 TVT procedures have been reported (41).  
The general public becomes more informed about medicine in general and their health in 
particular, which may mean that treatments known to have few or no side-effects are 
preferable to those for which unwanted side-effects have been recorded. The availability of 
multiple SUI treatment options with variable risk-benefit profiles underscores the need for 
detailed informed consent and discussions of woman’s goals and expectations. In a survey 
(2003) patients with SUI indicated that most of them preferred lesser invasive treatment, even 
if they would have to accept a lesser chance of cure (42). In this perspective, a minor invasive 
procedure, such as injection therapy with UBA’s, might be preferable compared to more 
invasive therapies as suburethral tape, colposuspension, and artificial urinary 
sphincterprothese. 
Randomized clinical trials (RCT’s) are needed to establish the place and efficacy of injection 
therapy with UBA’s compared with other treatments of SUI in adult women. Most studies of 
injection therapy with UBA’s were designed for ISD related SUI. If there was concurrent 
urethral hypermobility this could have been a reason for exclusion in such a study. Because 
the dichotomy mentioned above had changed into the direction of a continuum between ISD 
and urethral hypermobility, a RCT was designed to study the effect of UBA 
Macroplastique® in adult women with urodynamic stress urinary incontinence and urethral 
hypermobility after non-successful conservative treatment with measurement of VLPP as an 
indicator for ISD. 
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The aim of this thesis is to evaluate efficacy, safety, and durability of UBA’s using new 
techniques of transurethral injection as a minimally invasive procedure with quality of life 
aspects for SUI in adult women and to assess its place in a treatment algorithm of SUI. 
 
Chapter 2 presents a general review of injection therapy with different UBA’s for stress 
urinary incontinence in adult women. 
Chapter 3 discusses the efficacy and safety data of non-animal stabilized hyaluronic 
acid/dextranomer (NASHA/Dx) copolymer used for transurethral injection with a new 
guiding instrument (the Implacer) for stress urinary incontinence in adult women. 
Chapter 4 describes the effect on quality of life of this novel product (non-animal stabilized 
hyaluronic acid/dextranomer [NASHA/Dx] copolymer), injected transurethral with a new 
guiding instrument (the Implacer) for stress urinary incontinence in adult women. 
Chapter 5 discusses the durability of this non-animal stabilized hyaluronic acid/dextranomer 
(NASHA/Dx) copolymer for treating stress urinary incontinence in adult women. 
Chapter 6 contains a systematic review about the efficacy of another UBA, silicone 
microimplants (Macroplastique®) for stress urinary incontinence in adult women. 
Chapter 7 describes a randomised clinical trial of the Macroplastique® Implantation System, 
as a minimally invasive procedure in adult women with urodynamic stress urinary 
incontinence and urethral hypermobility after non-successful conservative treatment. 
A discussion and conclusions regarding injection therapy for stress urinary incontinence in 
adult women are presented in chapter 8. 
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Flowchart (management recommendation for SUI) from ICI 2005 (Abrams P, Artbani 
W, Cardozo L, Wein A. Clinical Manual of Incontinence in Women. Based on the Reports of 
the 3rd International Consultation on Incontinence 2005) 
 
Initial treatment: 
1. Assess oestrogen status and treat as appropriate, life style interventions, pelvic floor 
muscle training 
2. Other physical therapies, devices 
3. Dual serotonin and noradrenaline reuptake inhibitors (subject to local regulatory 
approval) 
If initial therapy fails: 
4. Surgery; injections, low tension slings, colposuspension, artificial urinary 
sphincterprothese 
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Abstract 
Stress urinary incontinence (SUI) is prevalent in adult women and has a considerable impact 
on quality of life. However, it often remains undiagnosed and therefore untreated. 
Noninvasive treatment is likely to be offered in mild cases and may entail pelvic floor muscle 
re-education, minimally invasive devices or pharmacotherapy. Surgical intervention is widely 
considered as the only effective option for more severe SUI, although it is not suitable for all 
patients. Injection therapy with urethral bulking agents represents an alternative minimally 
invasive procedure and can be used for all types of SUI. Many bulking agents have been 
developed, although the ideal remains to be discovered. The safety and durability of agents 
remain a concern. No differences in agents from an efficacy point of view have been found. 
For many years urethral injection could only be administered endoscopically. The recent 
development of devices for blind injection has increased the speed and convenience of 
urethral injection, removing the need for surgical facilities. The subjective cure rate after 
injection therapy is higher than the objective one. A focus on patient’s wishes and 
expectations with respect to success and risks of a treatment for SUI is required. In addition, 
randomized clinical trials are mandatory to establish the place and efficacy of urethral 
bulking agents compared with conservative therapy (pelvic floor muscle re-education) in 
treating SUI in adult women. 
 
Keywords: adult woman, injectable, urethral bulking agent, urinary stress incontinence. 
  
Introduction 
Stress urinary incontinence (SUI) is a common clinical problem in adult women and a 
significant cause of disability and dependence. The incidence of the condition increases with 
age (1). It can affect women of all ages and has a prevalence of 10-30% in girls and women 
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between 15 and 64 years, and more than 50% of nursing home residents (2). SUI affects 
around a third of women of childbearing age (3). The prevalence of SUI in adult women is 
liable to be under-estimated due to under-reporting and consequent under-diagnosis, as 
urinary incontinence is often considered to be an inevitable part of aging and an embarrassing 
and untreatable condition (4). Another issue is that prevalence studies are hampered by a lack 
of agreed definition of SUI. Increasing age and childbirth are relative risk factors of SUI, 
while other pre-disposing factors include obesity, smoking, previous urogenital surgery and 
restricted mobility (5). In a histological post mortem study, an age-dependent reduction in the 
number of striated muscle cells in the rhabdosphincter due to apoptosis was noted (77). 
SUI affects the physical, psychological and social well-being of a patient, thus having a 
considerable impact on quality of life (6). The patient and physician should discuss the 
available options for treating SUI, and patients should be informed of the relative benefits 
and risks for each option. The treatment options for SUI are pelvic floor muscle re-education, 
minimally invasive devices, pharmacotherapy, urethral injection and surgery. The choice of 
treatment will depend on the patient’s preference, condition, and urodynamic diagnosis and 
also the physician’s experience and preference. Injection therapy with urethral bulking agents 
for SUI seems to be an attractive option. The procedure is generally considered by patients 
and surgeons as minimally invasive. This article will present the current status of injection 
therapy with urethral bulking agents for treating SUI in adult women. 
 
Clinical presentation of SUI 
SUI is defined as the symptom of involuntary loss of urine associated with physical exertion 
(such as coughing, sport, and changes in position). It is a symptom, not a condition, which 
may be caused by pathological, anatomical or physiological factors (7). The International 
Continence Society (ICS) defines ‘urodynamic stress incontinence’ as the involuntary 
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leakage of urine, when the intravesical pressure exceeds the urethral resistance, as a result of 
increased intra-abdominal pressure in the absence of a detrusor contraction (7). Diagnosis 
based on this definition requires invasive urodynamic evaluation in addition to history taking, 
physical examination, frequency/volume charts and urine analysis. Invasive urodynamic 
evaluation, in addition to clinical assessment, is required for accurate diagnosis although its 
usefulness in improving outcome remains uncertain (11). SUI may be classified into three 
specific types according to anatomic classification of Blaivas (Table 1; 8), although this 
system requires video-urodynamics or cystoscopy and not all cases require such thorough 
investigation. Urethral hypermobility (Type 1 and 2) and intrinsic sphincter deficiency (ISD; 
Type 3) may (and often do) coexist in the same patient. The severity of incontinence may 
influence the type of treatment offered to patients. Pelvic floor muscle re-education should be 
considered as first-line therapy for mild SUI, while urethral injection or surgery are the likely 
candidates for patients with severe SUI (9). The extent to which urethral hypermobility and 
ISD contribute to the condition is another consideration in the treatment decision and has 
been identified as a key influence on the choice of surgical intervention (10). Although, there 
is still no evidence that such a distinction alters the outcome of treatment. 
 
Patient selection 
In general, optimal patient selection for injection therapy seem to be elderly women, patients 
with high operative risk, those who refuse open surgery, those following multiple previous 
pelvic surgery and radiotherapy, or those with SUI due to intrinsic sphincter deficiency (12). 
Injection therapy might also be a good option for those women who wish for 
pregnancy/delivery. Patients with SUI, caused by a combination of urethral hypermobility 
and intrinsic sphincter deficiency, with failure of urethral suspension, may also benefit from 
this procedure (12). Bladder neck hypermobility may decrease the success of injection 
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therapy (13-16). However, some studies have reported a positive outcome of periurethral 
collagen injections in patients with SUI caused by urethral hypermobility (17,18). In other 
studies, no differences in success between SUI with and without urethral hypermobility could 
be found (19-21). Success seemed to be independent of age, parity, previous pelvic surgery, 
severity of incontinence, or concomitant a small or mild cystocele (13,22-24). However, 
patients with no previous anti-incontinence surgery appear to have subjectively and 
objectively superior results in comparison with patients after previous anti-incontinence 
surgery (25). It is likely that pre-existent and de novo idiopathic detrusor overactivity are 
negative prognostic factors for success. Patients with gross pelvic organ prolapse are not 
suitable for injection therapy (26). 
 
Mechanism of action of injectables 
The basic principle of endoscopic injection of bulk-enhancing agents for treating SUI is the 
provision of an additional submucosal bulk in the area of the bladder neck (mid-urethra) in 
women. The mechanism of restoring continence after successful injection therapy remains 
unclear. Three possible mechanisms of action can be hypothesized: 
1. A bulking agent will augment the urethral mucosa, improve coaptation and intrinsic 
sphincter function, resulting in an increase of urethral closing pressure and restoring urinary 
incontinence (27).  
2. Radley and colleagues reported that firm nodules were realized 6 weeks after 
polydimethylsiloxane implantation submucosal in the proximal urethra (28). These findings 
suggest that the mechanism of action of polydimethylsiloxane is augmentation of pressure 
transmission to the proximal urethra by producing focal and firm expansion of periurethral 
tissue (28). In some studies an obstructive component with a decrease in maximum flow and 
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an increase in maximum detrusor pressure has been reported (17,29,30). Other authors have 
suggested that obstruction is not the mechanism of restoring continence (12,14,31,32).  
3. In successfully treated patients, injections result in a cephalad elongation of the urethra 
with a concomitant increase in pressure transmission ratio in the first quarter of urethral 
length. These changes are due to adequate injection at the bladder neck or proximal urethra 
preventing bladder neck opening during stress (12,14,31,32). Therefore, exact placement of 
the injection material is important to achieve continence. 
The choice of bulking agent is crucial to the safety and efficacy of urethral injection for SUI. 
The ideal agent should be nonimmunogenic, biocompatible, nontoxic and hypoallergic. 
Moreover, a bulking agent should be effective and demonstrate anatomical integrity, bonds to 
local tissues with minimal inflammation, retain its injected volume, not migrate to vital 
organs (particle diameter greater than 80 µm), should be easy to use and be cost effective 
(33). 
 
History of injectables  
For many years various injectables or urethral bulking agents have been used in treating SUI 
in adult women. In 1938, Murless produced the first report after injection of a sclerosing 
solution (sodium morrhuate) into the anterior wall of the vagina of 20 incontinent women, 
obtaining temporary scarring of the juxtaurethral tissue (34). In 1955, Quackels described 2 
cases treated with paraffin injection into the perineum, restoring continence by compression 
of the membranous urethra (35). In 1963, Sachse described the use of the sclerosant Dondren 
into the urethra with some success (36). Local tissue damage and pulmonary complications, 
including pulmonary infarction and emboli, restricted continuation of their use. In the early 
1970s, Berg (37) and Politano (38) first described the use of polytetrafluoroethylene (PTFE; 
Teflon®) injections around the urethra. Evidence of urethral scarring due to fibrosis, 
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granuloma formation at injection site, particle migration, carcinogenic potential has now 
stopped the clinical use of this product (39-45). Another agent, autologous fat, is attractive in 
terms of reduced immunogenicity. Fat cells are harvested from the abdominal wall by 
liposuction. One study compared periurethral injection of this agent with placebo injection of 
saline and no difference was found in subjective or objective outcome measures between the 
two groups (46). One death attributed to fat embolization, urethral lipoma, and connective 
tissue replacement has been reported after autologous fat injection (47-49). The poor efficacy 
and unsatisfactory safety profile of this injectable have resulted in its discontinuation of use 
as a urethral bulking agent (50). 
 
Current available injectables  
A list of currently available injectables, as discussed below, is provided in Table 2. 
Bovine collagen 
Bovine collagen (Contigen®) is well established as bulking agent for urethral injection. No 
risk of granuloma formation or migration with this agent has been reported (27).  However, 
allergic reaction occurs in approximately 4% of females. Therefore, preinjection skin testing 
must be performed 30 days prior to treatment (33). The initial success rate (cure/improved) of 
collagen injection therapy for ISD is 85 – 94% (33,51). However, the proportion of patients 
remaining continent declines considerably over time following collagen injection. The long-
term (greater than 2 years) success rate is not as favorable (26 – 65%) (33,52). Repeat 
injections are usually required in the majority of patients to achieve continued continence 
(19). This may be attributable to in vivo degradation of the implant, a phenomenon that has 
been noted in animal studies (53). The overall complication rate for collagen injection is 
20%; urinary tract infection 4%, hematuria 5%, transient urinary retention 1.9 – 8%, de novo 
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urgency 12.6%, and delayed skin reaction associated with athralgia 0.9% (33,54). Cost 
effectiveness remains a concern due to the need for repeat injections (55). 
 Silicone 
Silicone (Macroplastique®) is a soft tissue-bulking agent and is comprised of soft, flexible, 
highly textured irregularly shaped implants of heat vulcanized polydimethylsiloxane (a solid 
silicone elastomer), suspended in a bioexcretable carrier gel. The particle sizes of 
polydimethylsiloxane varied between 120 and 264 µm (56,57). The risk of biodegradation 
and migration of polydimethylsiloxane appear to be nonexistant (56). No evidence has been 
reported that silicone elastomers are associated with connective tissue disease (58). The agent 
must be injected with a high-pressure injection gun due to its viscous nature. 
Recently, a systematic review has been preformed to assess the efficacy of silicone 
microimplants for treating SUI in adult women (59). Reported cure and success rates (cured 
and improved) using silicone microimplants for only intrinsic sphincter deficiency varied 
between 14 and 66.7%, and 46 and 80%, respectively. For intrinsic sphincter deficiency with 
urethral hypermobility, the cure and success rates varied between 0 and 21.4%, and 0 and 
58.9%, respectively. Follow-up of the studies varied between 3 months and 3 years and 
showed decreased success rates in six studies (13,15,22-24,60). None of the studies reported 
major complications during or after the procedure. Only minor and transient complications, 
including dysuria, frequency, hematuria, postoperative pain, and urinary retention requiring 
intermittent catheterisation, have been described. The included studies showed a poor 
methodological quality and, therefore, results should be interpreted with caution. 
Carbon-coated zirconium beads 
Carbon-coated zirconium beads in a gel containing β-glucan (Durasphere®) is the most 
recent bulking agent to be approved by the US Food and Drug Administration (FDA) in 
1999. The beads are nonantigenic and size ranges from 251 to 300 µm (61). Although 
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carbon-coated zirconium beads are reported as being nonmigratory (61), Pannek and 
colleagues observed migration into local and distant lymph nodes (62). 
A recent study conducted in 355 women compared the safety and efficacy of carbon-coated 
zirconium beads with bovine collagen for the treatment of ISD (61). At 12 months after the 
first injection, 80.3% of women in the carbon-coated zirconium beads group had 
improvement in continence grade versus 69.1% in the bovine collagen group. However, no 
significant difference in subjective and objective outcome between the two groups was noted. 
Fewer carbon-coated zirconium beads were injected in order to obtain comparable clinical 
results. The adverse events reported for both groups were similar; the carbon-coated 
zirconium beads had an increased short-term risk of urgency and urinary retention. 
Calcium hydroxylapatite 
Calcium hydroxylapatite (Coaptite®) is a synthetic version of material found naturally in 
bone and teeth. It is a nonantigenic bulking agent consisting of hydroxylapatite spheres in an 
aqueous gel composed of sodium carboxylmethylcellulose. Calcium hydroxylapatite is 
formulated to prevent distant migration (particle size 75–125 µm) (63). Animal studies have 
shown this material to be biocompatible, nonencapsulating, and adhesive to in-growing 
collagen fibres with little inflammation. Plain film radiography or ultrasonography will 
identify calcium hydroxylapatite at the injection site (33).  
In a pilot study, ten women with a history of SUI (ISD with limited urethral hypermobility) 
were treated with calcium hydroxylapatite particles as a bulking agent (63). Three women 
received one injection and seven received two injections. At 12 months after the last 
injection, seven women reported substantially improved continence and two used fewer pads. 
No adverse events were identified and migration was not reported. 
Dextranomer/hyaluronic acid (Dx/HA) copolymer 
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Dextranomer/hyaluronic acid (Dx/HA) copolymer (Zuidex®) comprises dextranomer 
microspheres (80–250 µm) in a gel of nonanimal stabilized HA. Both constituents are 
biocompatible, biodegradable and nonimmunogenic, and carry no risk of migration (64-66). 
Dx/HA copolymer has been demonstrated to be stable, and has a high safety and efficacy 
profile (65,67,68). A preliminary 3-month clinical study to examine the efficacy and safety of 
Dx/HA copolymer for the treatment of SUI has been conducted in 20 women with ISD and/or 
hypermobility (65). After 3 months 17 of the 20 patients were cured or showed improvement 
and there was no decline in the 17 women followed for a further 3 months. One case of 
granuloma formation causing urinary obstruction in a woman has been reported 5 years after 
injection of Dx/HA copolymer (78). 
Ethylene vinyl alcohol copolymer 
Ethylene vinyl alcohol copolymer (Uryx®) is dissolved in a dimethyl sulfoxide (DMSO) 
carrier. Upon contact with an aqueous environment, such as the submucosal tissues of the 
urethra, the DMSO solvent diffuses away, resulting in precipitation of the copolymer, which 
forms a cohesive spongy mass, creating a bulking effect. A large-scale North American trial 
is in progress. At 12 months, 74% of 40 Uryx patients were dry compared with 40% of 23 
collagen patients. Rates of postimplantation urgency and dysuria were the same across both 
groups (79).  
Experimental agents 
The search for urethral bulking agents that fulfill the ideal criteria continues. Currently, 
agents as silicone microballoons, alginate gels, autologous ear chondrocytes and autologous 
myoblasts are subjects in phase 1 and 2 studies (50). Autologous chondrocytes are isolated 
from ear cartilage, expanded in culture and formulated with calcium alginate to form an 
injectable gel. In a preliminary study, 32 women with ISD were treated with a single injection 
of autologous chondrocytes. Using both objective and subjective measures, 50% of the 
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patients were dry at 12 months. Of 32 patients (81.3%), 26 were dry or improved at 3 months 
after the injection and maintained the effect at 12 months (80). In a study in male rats, muscle 
precursor cells from limb myofiber explants were isolated, and injected into the damaged 
sphincter of the same animal. Motor units were formed that contract under stimulation of 
sphincteric nerves and partial restoration of sphincteric function was noted (81).  
 
Injection techniques 
Trans- and periurethral administration 
The endoscopic injection procedure can be performed under general, regional or local 
anaesthesia. During the transurethral procedure, under direct cystoscopic vision the needle is 
placed submucosally into the urethra at the 6, 10 and 2 o’clock positions, 1.5 to 2.0 cm distal 
from the bladder neck. The material is slowly injected until a sufficient mucosal bleb is 
achieved. The procedure is completed if there is a total mucosal apposition together with 
occlusion of the urethral lumen. The injectable can also be administered periurethrally. This 
procedure is performed under cystoscopic control by inserting a spinal needle percutaneously 
adjacent to the urethra. After injecting, the cystoscope should not be advanced past injected 
areas and only small in and out catheters (8-12 Fr) should be inserted, as this may result in 
compression or extrusion of the bulking agent.  
An important aspect of endoscopic administration is accurate positioning of the implant to 
achieve continence (27,69). An endoscopic procedure seems to be superior to periurethral 
application or ultrasound-guided injection for treating incontinence (70). Radley and 
colleagues reported success to be associated with complete encirclement of the urethra by 
polydimethylsiloxane (25). If polydimethylsiloxane treatment failed, transvaginal or 
transurethral ultrasound could be performed to investigate correct placement of 
polydimethylsiloxane. 
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Precise placement of the bulking agent is difficult because of the mobility of the urethra and 
folding of the inner epithelium. Care is required to ensure that the needle is not placed too 
close to the urethral lumen to avoid the risk of mucosal rupture and extravasation. In addition, 
the second and third injections must be positioned correctly with respect to the first injection, 
as there is a risk of puncturing the previous implant.  The need for precision is complicated 
by impaired vision from the endoscope, owing to the need for a continual water flush. 
Probably, these factors have contributed to the variability in published outcomes with urethral 
injection.   
Semi-automated devices 
To improve, simplify and standardize the transurethral implantation technique, and to 
minimize problems associated with endoscopic procedures, devices allowing blind 
administration of urethral injection have recently been developed specifically for use with 
silicone and Dx/HA copolymer. This procedure can be performed under local anesthesia in a 
consulting room without surgical facilities. The Macroplastique® Implantation System (MIS) 
was the first to administer blind urethral injection (Figure1). The device allows constant 
placement of the implants at predefined depths and angles at the 6, 10 and 2 o’clock position 
of the mid-urethra within the same circumferential plane. In order to identify the site of 
implantation correctly, the ruler measuring-scale on the topside of the device is used. The site 
of the bladder neck is identified as the position where the water flow from the fluid drainage 
channel ceases while the tip of the device is slowly withdrawn from the fluid-filled bladder. 
The standard implantation position is defined by withdrawing the device from the urethra to 
the appropriate location of the mid-urethra, i.e., a 10-15 mm distance from the level of the 
bladder neck.  
Henalla and colleagues reported a 3-month study of the safety and efficacy of the MIS in 40 
women with SUI, which included assessment of patient and physician acceptability of the 
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procedure (71). Operator acceptance of this procedure was excellent or acceptable in 95% 
after first treatment and 100% after retreatment. Urethral insertion was rated as acceptable in 
92.5% of the procedures. In 89% of the implantation procedures, mild or moderate pain was 
experienced. An overall success rate of 53% was reported 3 months after the first treatment, 
increasing to 74% after retreatment. Another study reported 12-month results of this system 
in 21 women with ISD (72). The study demonstrates a subjective rate of cure of 57.1% and 
cure/improvement of 76.2%. Surgeon assessment revealed a decrease in cure and 
improvement from 90.5 to 66.7% after a 6-month period. Urodynamic testing (using Valsalva 
leak point pressure) demonstrated that eight patients (40%) were dry and one (5%) was 
improved. 
The Implacer® device has been developed for blind administration of Dx/HA copolymer 
using four syringes and needles (Figure 2). This device is inserted to a depth that is 
predetermined according to urethral length, while the four needles are held parallel to the 
urethral channel. The needles are then released outwards, stretching the urethra and holding 
the mucosa in a fixed position. One by one, the syringes are retracted by 5–10 mm, then 
advanced fully for submucosal injection of Dx/HA copolymer.  
A recent study investigated the efficacy and safety of nonanimal stabilized hyaluronic 
acid/Dx copolymer using the Implacer® device in 42 women with SUI (urethral 
hypermobility or ISD). Significant reduction in median urine leakage was observed, from 36 
g at baseline to 5.5 g at 3 months, sustained at 12 months. After 3 and 12 months, 32 (76%) 
women demonstrated a degree of improvement in urine leakage (18 received a second 
injection). The mean number of incontinence episodes per day significantly decreased from 
1.9 at baseline to 0.4. The treatment was well tolerated and no complications were reported 
(73). 
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Expert Opinion 
SUI is a common condition among women following childbirth and post menopause. The 
range of treatment options, their outcomes and possible complications must be discussed with 
the patient before treatment commences. Treatment should be offered sequentially, beginning 
with the least invasive therapy. Surgery is often considered as the only effective option for 
women with SUI who do not respond to pelvic floor muscle re-education or 
pharmacotherapy. However, there are several drawbacks with surgery including the risk of 
complications and the lack of suitability for women likely to conceive in the future. 
Injectables are suggested to offer several potential advantages over surgical procedures, 
including lower morbidity, shorter procedure time, shorter inpatient stay and more rapid 
recovery (74). The procedure is most commonly based on day-case care and use of local or 
regional anaesthesia. Injection therapy can be used for all types of SUI. Future childbirth is 
unlikely to be considered as a contraindication. Safety profile and durability of bulking agents 
remain a concern. The ideal bulking agent has not yet developed. To simplify, improve, and 
standardize the endoscopic procedure, new devices for blind administration of bulking agents 
have been developed. These systems seem to have promising results for the patient and 
surgeon. 
In the Cochrane Database of Systematic Reviews, a systematic review of the effectiveness of 
periurethral injection therapy for urinary incontinence in women has been reported (75). As 
only small number of studies has been identified (seven randomized trials, and five of the 
studies were abstracts) and the paucity of published data, statistical analysis was 
inappropriate and prevented meta-analysis. The data suggested subjective and objective 
short-term improvement of SUI in women and that the transurethral route results in fewer 
complications (less retention and urinary tract infection compared with paraurethral 
injection). No difference in subjective outcome was reported between injection therapy and 
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surgery, although more patients were cured (using 24-hr pad test) after surgery. The 
complications were significantly more frequent and severe in the surgery group. No data are 
available comparing injection therapy with pelvic floor muscle training. Furthermore, no 
injection material is superior at present.  
In two studies, the subjective success rate following injection therapy was higher than the 
objective one (18,72). A recent survey of patients with SUI demonstrated that most patients 
prefer less invasive therapy, even if the chance of cure may be lower than with major 
procedure (76). Therefore, a focus on patient’s wishes and expectations with respect to 
success and risks is required.  
 
Five-year view 
Continuous advancements in injectable agent materials and delivery techniques will evolve in 
the next 5 years. Experience continues to accrue in randomized clinical trials with urethral 
bulking agents for treating SUI in adult women. 
Knowledge of the safety, efficacy and durability of the agent, delivery techniques, quantity 
and site of injection are being gained. Injection therapy for treating SUI in adult women may 
have a place between conservative therapy (pelvic floor muscle exercises) and surgery. 
 
Conclusion 
Injection therapy with urethral bulking agents would be a good option as treatment for SUI 
after failing conservative therapy. Randomized clinical trials (RCT) of urethral bulking 
agents compared with conservative treatment (pelvic floor muscle re-education) and placebo 
are required, with a long follow-up and health economic analysis to provide evidence of 
efficacy, cost-effectiveness, and risks. A randomized clinical trial to evaluate efficacy and 
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acceptability by patient and physician using the MIS for the treatment of SUI in women 
compared with pelvic floor muscle exercises is scheduled for the near future. 
 
Key issues 
•  Stress urinary incontinence (SUI) is prevalent in adult women and has a 
considerable impact on quality of life. However, it often remains undiagnosed and 
therefore untreated. 
•  Injection therapy with urethral bulking agents is a minimally invasive procedure 
and can be used for all types of SUI. Many bulking agents have been developed, 
although the ideal remains to be discovered. 
•  The subjective cure rate following injection therapy is higher than the objective 
one. A focus on patient’s wishes and expectations with respect to success and 
risks of a treatment for SUI is required. 
•  Randomized clinical trials are mandatory to establish the place and efficacy of 
urethral bulking agents compared with conservative therapy in treating SUI in 
adult women. 
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Table 1. Classification of stress urinary incontinence (8). 
Classification of 
SUI 
Description of symptoms 
Type I Bladder neck and urethra open and descend during stress. Descent 
less than 2 cm, no evidence of cystocele. 
Type IIA Bladder neck and urethra open and descend during stress. Descent 
less than 2 cm, evidence of cystocele. 
Type IIB Bladder neck and urethra closed and below the symphysis pubis at 
rest. Possible descent during stress, urethra open. 
Type III Bladder neck and urethra open at rest, absence of detrusor contraction 
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Table 2. Technical information of current available injectables. 
Agent  Marketed name  Particle size Characteristic  Success (%) 
     (µm)       
      
Bovine collagen Contigen®  NA  Rapidly absorbed 26-65 (>2yrs) 
       Allergic reaction    
       Refrigeration required   
Silicone  Macroplastique®  120-264  Viscous   46-80 (3m-3yrs) 
       Stable 
 
Carbon beads Durasphere®  251-300  Nonantigenic  80.3 (1 yr) 
       Viscous  
       Migration     
Calcium  Coaptite®  75-125  Nonantigenic  Trials in progress 
hydroxylapatite      Stable 
       Radiolucent 
Dextranomer/ Zuidex®  80-250  Significant elasticity 76 (1 yr.) copolymer 
hyaluronic acid      High viscosity    
       Biodegradable    
       Nonimmunogenic   
       Granuloma formation  
 
Ethylene vinyl Uryx®   NA   Solidification  Trials in progress 
alcohol copolymer                
NA = not applicable, yr (s) = year(s), m = months 
Success: Improvement of stress urinary incontinence and dry. 
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Figure 1. Macroplastique® implantation device for delivery of silicone. One needle is 
transferred between each of the three deployment sites to complete the urethral injection. 
 
Figure 2. The Implacer® device for delivering dextranomer/hyaluronic acid copolymer; A) 
Ready for insertion into the urethra, B) Positioned within the urethra prior to injection from 
each of the four syringes. 
 
  A)  B)  
 
 
  
Page 45 
Chapter 3 
Efficacy and safety of a novel system (NASHA/Dx copolymer 
using the Implacer device) for treatment of stress urinary 
incontinence 
 
Philip van Kerrebroeck a, Flip ter Meulen a, Gregor Larsson b, Elisabeth Farrelly c , Lena 
Edwall d, and Aino Fianu-Jonasson d 
 
a Department of Urology, University Hospital Maastricht, the Netherlands 
b Department of Obstetrics and Gynecology, Västerås Central Hospital, Västerås, Sweden 
c Department of Urology, Karolinska Hospital, Stockholm, Sweden 
d Department of Obstetrics and Gynecology, Huddinge University Hospital, Stockholm, 
Sweden 
 
 
 
 
 
 
 
 
 
Journal: Urology 2004;64(2):276-281. 
  
Page 46 
Abstract 
Objectives. To investigate the efficacy and safety of non-animal-stabilized hyaluronic 
acid/dextranomer (NASHA/Dx) copolymer for transurethral injection using a new guiding 
instrument (the Implacer) for stress urinary incontinence. 
Methods. In an open, prospective, multicenter study, 42 invasive therapy-naive female 
patients with stress urinary incontinence were given 4 x 1.0 ml or 4 x 0.7 ml of NASHA/Dx 
copolymer using the Implacer. The efficacy parameters, measured at baseline, and 1, 3, 6, and 
12 months after treatment, included cough-induced leak point pressure, urine leakage by 
provocation test, number of incontinence episodes in 24 hours, and patient perception of 
bladder condition, rated on a 6-point scale. 
Results. The collected cough-induced leak point pressure data were not judged to be valid 
and reliable. Statistically significant reductions in median urine leakage were observed (P 
<0.0001), from 36 g (range 0.0–300) following 20 ‘jumping jacks’ or vigorous coughs at 
baseline to 5.5 g (range 0.0–98) at 3 months and sustained at 12 months (7.0 g, range 0.0–98). 
Of the 42 patients, 32 (76%) demonstrated a degree of improvement in urine leakage at 3 and 
12 months. The median number of incontinence episodes in 24 hours decreased significantly 
from 1.9 (range 0.0–24) at baseline to 0.4 (range 0.0–24) at 12 months (P <0.0001). At both 3 
and 12 months, 29 patients (69%) had improved by at least one category on the 6-point 
patient perception scale. Treatment was well tolerated, and no complications were reported 
with use of the Implacer. 
Conclusions. The results of this study indicate that a novel system (NASHA/Dx copolymer 
insertion using the Implacer) is an effective and well-tolerated treatment for invasive therapy-
naive patients with stress urinary incontinence, with improvement sustained for at least 12 
months. These encouraging results warrant additional study.  
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Key words: urinary incontinence, stress; female; urethral injection; non-animal-stabilized 
hyaluronic acid; NASHA/Dx copolymer. 
Zuidex™ and Implacer™ are trademarks of Q-Med AB, Uppsala, Sweden. 
 
Introduction 
Stress urinary incontinence (SUI), characterized by the involuntary leakage of urine, is a 
condition with a considerable impact on quality of life. Two etiologic mechanisms have been 
postulated: hypermobility and intrinsic sphincter deficiency (ISD), and the two mechanisms 
may co-exist in most patients.1 
First-line treatment is usually noninvasive (eg, physiotherapy), with pharmacotherapy another 
option. Surgery has been widely considered the only effective next treatment, but it is not 
suitable for all, and fear of complications may act as an obstacle. Endoscopic urethral 
injection has gained limited acceptance, with the durability and safety of the injected material 
a concern.2 A clear need exists for the development of a new, effective approach for the 
treatment of SUI. 
NASHA/Dx copolymer comprises dextranomer (Dx) microspheres (80 to 250 µm) in a 
carrier gel of non-animal stabilized hyaluronic acid (NASHA). The gel is a biocompatible, 
biodegradable material free from animal products, which has no immunogenic properties,3,4 
and has been shown not to migrate to different organs after submucosal injection.5 
NASHA/Dx copolymer is the only injectable agent approved by the U.S. Food and Drug 
Administration for endoscopic treatment of vesicoureteral reflux in children and has also 
gained European approval for the treatment of SUI. 
A new guiding instrument – the Implacer – has been developed to facilitate reproducible and 
standardized transurethral injection of NASHA/Dx copolymer, without the need for surgical 
facilities or cystoscopic guidance. This device comprises a holder that is placed into, and 
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fixates, the urethra (ie, distends the urethral circumference, thus smoothing out the 
longitudinal folds), allowing use of four syringes to inject implants at approximately the 2, 4, 
8, and 10 o’clock positions.   
This study was undertaken to investigate a novel system, transurethral injection of 
NASHA/Dx copolymer using the Implacer, in invasive therapy-naive female patients with 
SUI. 
Materials and methods 
This was an open, prospective, multicenter study, conducted in accordance with the 
principles of the Declaration of Helsinki, and approved by appropriate independent ethics 
committees. All participants provided written informed consent. Study treatment comprised 4 
x 1.0 ml (n = 32) or 4 x 0.7 ml (n = 10) injections of NASHA/Dx copolymer (Q-Med AB, 
Uppsala, Sweden) administered via the Implacer (Zuidex system: four NASHA/Dx 
copolymer-filled syringes and the Implacer, Q-Med). The original protocol specified 4 x 1.0 
ml, but was amended to also investigate a lower treatment volume (4 x 0.7 ml). 
The inclusion criteria were women 18 years of age or older with SUI verified by 
demonstrable leakage on coughing or Valsalva maneuver; a history of SUI for at least 12 
months; invasive therapy (ie, no previous surgical therapy for SUI); and failure with prior 
noninvasive treatment (eg, behaviour modification, pelvic floor exercises, drug therapy). The 
pathophysiology of SUI (ie, hypermobility and/or ISD) was not determined. 
The exclusion criteria were a mean volume voided of less than 200 ml; post-void residual 
urine (PVRU) of greater than 100 ml; urge incontinence; detrusor overactivity; medication 
for SUI; recurrent urinary tract infection; and anticoagulant or immunosuppressive therapy. 
General and/or local anesthesia was administered, depending on investigator preference. The 
Implacer was assembled using four syringes containing NASHA/Dx copolymer with 50-mm 
21-gauge needles attached (Fig. 1A). The four needles were covered by a cylinder sliding 
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through the handle and inserted into the urethra (Fig. 1B). The cover was retracted to release 
the four needles outwards at the designated mid-urethral position (Fig. 1C).6 Sequentially, 
each needle was retracted 5–10 mm, and pushed forward to penetrate the mucosa, thus 
allowing injection of the NASHA/Dx copolymer. Patients were required to void before 
leaving the clinic, and the PVRU volume was measured. Patients not responding to the initial 
treatment were offered one repeat treatment 1 to 2 months after the first procedure, using an 
identical method.  
Follow-up visits were scheduled at 1, 3, 6, and 12 months, with treatment efficacy parameters 
assessed at baseline and each of these points. The primary endpoint was the change from 
baseline in cough-induced leak point pressure (CILPP).7 Secondary assessments included 
urine leakage by provocation test, measured by pad weight before and after 20 ‘jumping 
jacks’ or vigorous coughs, and performed with 300 ml saline in the bladder; and the number 
of incontinence episodes in 24 hours, assessed by a 1-week micturition chart. Given that these 
tests did not form part of the inclusion criteria, 1 patient did not show leakage at baseline by 
provocation test and 1 patient had no incontinence episodes in 24 hours. The patients’ 
perception of their bladder condition was also assessed, with bother graded on a 6-point scale 
as no, some very minor, some minor, some, some severe, and many severe problems. 
Safety assessments included adverse event (AE) monitoring and PVRU measurement at each 
visit, with maximum cystometric capacity and maximum urethral closure pressure (MUCP) 
assessed up to 6 months before the baseline visit, and at the 1, 3, 6, and 12-months. 
Statistical analyses were performed using the Statistical Analysis System software,8 the 
intention-to-treat principle, and the last observation carried forward method. Sample size was 
determined based on 95% power, a statistical significance level of 5% and an increase in the 
CILPP of 30 cm H20. However, the collected CILPP data were not judged to be valid and 
reliable, and a statistical analysis was performed using only descriptive statistics. Changes 
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from baseline in urine leakage by provocation test and number of incontinence episodes in 24 
hours were analysed by Wilcoxon signed rank test, with a two-tailed probability of 0.05 or 
less considered statistically significant. The data were not normally distributed, consequently 
the median values are given. The data for the patients’ perception of their bladder condition 
were analyzed using descriptive statistics. 
Results 
A total of 49 individuals were screened, of whom 42 were recruited into the study. Of these, 
32 received 4 x 1.0 ml and 10 received 4 x 0.7 ml. Seven patients were not included in the 
study because consent was withdrawn (n = 2), of personal problems (n = 1), of a broken leg 
(n = 1), no leakage occurred at urodynamic investigation (n = 1), of social reasons (n = 1), 
and of personal reasons (n = 1). The demographic variables and baseline incontinence 
parameters are presented in Table 1.  
Between the baseline and 3-month follow-up visit, 1 patient was lost to follow-up and 1 
patient withdrew consent; 4 patients were lost to follow-up between the 3 and 12-month 
visits.  
Three patients (7%) were withdrawn from further follow-up because of a lack of efficacy 
between the baseline and 3-month visits, as assessed by the patients’ perception of treatment 
benefit (ie, whether the patient considered their incontinence problems improved since their 
last visit). Seven patients (17%) were withdrawn between 3 and 12-month follow-up visits 
because of a lack of efficacy. 
Given that the two dosage groups showed very similar efficacy results, we combined the data 
and considered as one group in the efficacy evaluation. The assessment of the CILPP showed 
that at 3 months, 13 (42%) of 31 patients had no leakage, and, compared with baseline, 10 
(32%) had improved (increased CILPP), and 8 (26%) had worsened (decreased CILPP). The 
corresponding values at 12 months were 14 (64%), 4 (18%), and 4 (18%) of 22 patients. 
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Statistically significant reductions in median urine leakage as measured by the provocation 
test were observed after treatment at 3 months and sustained at 6 and 12 months (P <0.0001 
versus baseline; Fig. 2A). The number of patients demonstrating a degree of improvement in 
urine leakage at 3 and 12 months compared with baseline is shown in Table 2, with 32 (76%) 
of 42 patients improved at both points. Statistically significant reductions in the median 
number of incontinence episodes in 24 hours were also observed, again sustained at 12 
months (P <0.0001 versus baseline; Fig. 2B). At the 3-month follow-up visit, 29 (69%) of 42 
patients were improved by at least one category on the 6-point patient perception scale, with 
the same percentage improved at 12 months. 
Eighteen patients underwent one repeat treatment because of an insufficient response, with a 
mean time between the first and second injections 48.9 days (range 24.0 to 65.0). At 3, 6, and 
12 months, statistically significant reductions in the median urine leakage as measured by the 
provocation test and the median number of incontinence episodes in 24 hours was observed 
in both the re-treated patients and those not requiring re-treatment (P <0.014 versus baseline, 
for all 12 scenarios).  
Treatment-related AEs, which were transient and as expected following urethral injection, 
were reported by 15 patients (36%). For the 4 x 1.0-ml group, apart from 1 patient with a 
sterile abscess, all treatment-related AEs were urinary system disorders, with the most 
common urinary tract infection (n = 5), haematuria (n = 4), urethral disorder (n = 3), and 
decreased urinary flow (n = 3). Fewer AEs were observed in the 4 x 0.7-ml group (urinary 
tract infection in 1 and urinary retention in 1). 
Almost all treatment-related AEs were of mild (70%) or moderate (26%). No complications 
were reported in relation to the use of the Implacer. Three treatment-related AEs involving a 
PVRU of greater than 100 ml led to temporary catheterization. Catheterization was started on 
the day of treatment and lasted for a mean of 4 days (range 2 to 8 days). 
  
Page 52 
No statistically significant changes were observed in the MUCP or maximal cystometric 
capacity compared with baseline at any point. Although the reduction in absolute urine 
leakage tended to be greater in the 5 patients with an MUCP of 20 cm H2O or less, no 
noticeable difference was observed in the relative reduction in leakage between these patients 
and those with greater MUCP values. 
Comment 
This is the first study investigating the treatment of SUI with NASHA/Dx copolymer 
administered via the Implacer. Valid and reliable results could not be obtained for the 
primary endpoint, the change from baseline in CILPP, because CILPP was not measured 
consistently among the centers, values proved difficult to verify, and a large number of values 
were missing. This did not invalidate the other efficacy results, which showed sustained 
efficacy over time. Sustained and statistically significant improvements in quality of life (P 
<0.005), as assessed by the King’s Health Questionnaire were also observed.9 
Sixty percent of patients received only one injection procedure. Urethral injection with other 
bulking agents often require multiple injections, particularly collagen where up to five 
injections (ie, four retreatments) have been used.10,11 Statistically significant and sustained 
improvement was observed even if repeat treatment was required.  
Whether the presence of hypermobility or ISD influenced the treatment outcome was not 
directly assessed. Nevertheless, this issue is worth addressing given that it has been 
investigated in other studies. Injectable agents are restricted to patients with ISD in some 
countries, but the concept of ISD and hypermobility dichotomy has been questioned. The 
International Continence Society has stated that delineation into such categories may be 
simplistic and arbitrary.12 ISD may co-exist in many patients previously categorized as 
hypermobile,1 and increasing data show that injectable agents are also effective in patients 
with hypermobility.13,14  
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The treatment was well tolerated, with fewer AEs in the 4 x 0.7-ml than the 4 x 1.0-ml group. 
Patients receiving the lower volume were treated later in the study, at the same center. 
Therefore, the difference may be explained by a learning curve for the device or reporting 
variation, although the possibility the lower volume produces fewer AEs cannot be excluded. 
The Implacer offers a standardized and guided injection technique, allowing injection of 
NASHA/Dx copolymer at specific sites, without the need for surgical facilities. Although the 
implants are not visualized during administration, magnetic resonance imaging of patients in 
this study demonstrated that the implants were deposited into the desired periurethral location 
in the urethral submucosa in most cases.15  
Histopathologic data have shown that NASHA/Dx copolymer induces only a mild 
inflammatory reaction in contrast to the foreign body reactions and potential granuloma 
formation observed with other bulking agents (particularly silicone and 
polytetrafluoroethylene).3, 16 The lack of a negative effect of NASHA/Dx copolymer on the 
surrounding tissue means that subsequent surgical procedures are not affected. In 3 subjects 
in the present study who did not respond adequately, tension-free vaginal tape procedure was 
performed as normal, without complications.17  Dx microspheres have been shown to persist 
for more than 3 years after injection.16 Accordingly, sustained clinical efficacy for at least 5 
years has been observed in children with vesicoureteral reflux, together with an absence of 
long-term AEs.18 Moreover, after a 6.5-year follow-up period, 57% of patients were still 
cured or improved in a preliminary study of NASHA/Dx copolymer injected endoscopically 
in 20 patients.19, 20 Longer-term results with NASHA/Dx copolymer via the Implacer are 
awaited. 
The present results have implications for the management of SUI. Patients in who 
noninvasive treatment fails are generally offered surgery. However, in a recent study, a major 
operation was unacceptable to most women, and a clinic procedure with lower success and no 
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long-term risk was preferred.21 Where surgery is not an option, NASHA/Dx copolymer 
appears to be of benefit, with the number of individuals receiving active treatment potentially 
increased. 
Conclusions 
The results of the present study indicate that a novel system, NASHA/Dx copolymer using 
the Implacer, is an effective and well-tolerated treatment for patients with SUI who have not 
undergone invasive therapy, with improvement sustained for at least 12 months. The lack of a 
requirement for surgical facilities and the established safety profile of NASHA/Dx copolymer 
further support the use of this new SUI treatment. 
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* Patients’ perception of bladder condition graded as some severe, or many severe, problems 
on a 6-point scale. 
 
 
Table 1. Patient demographics and baseline characteristics 
 4 x 1.0 ml 
(n = 32) 
4 x 0.7 ml 
(n = 10) 
Demographic variables 
 Mean age, years (range) 
 Mean body mass index, kg/m2 (range) 
 Menopause, n (%) 
 Deliveries 0–2, n (%) 
 Deliveries 3–4, n (%) 
 Duration of symptoms >5 years, n (%) 
 Severe problems (patient perception) *, n (%) 
 Previous nondrug therapy for SUI, n (%) 
 
52.9 (35.2–70.1) 
24.7 (19.0–34.3) 
17 (53%) 
22 (69%) 
10 (31%) 
24 (75%) 
18 (56%) 
32 (100%) 
 
52.3 (30.5–77.9) 
23.6 (20.1–28.7) 
5 (50%) 
7 (70%) 
3 (30%) 
9 (90%) 
4 (40%) 
10 (100%) 
Baseline characteristics  
 Urine leakage by provocation test, g, median (range)  
 Number of incontinence episodes/24 hours, median (range) 
 Maximum urethral closure pressure, mean (range) 
 Maximum cystometric capacity, mean (range) 
 
40 (0–300) 
1.8 (0.0–24.0) 
43.3 (9.0–86.0) 
501 (170–960) 
 
30 (16–70) 
2.2 (0.4–7.1) 
47.2 (35.0–64.0) 
386 (318–515) 
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Table 2. Patients demonstrating improvement or no improvement in urine leakage as measured 
by provocation test at 3 and 12 months compared with baseline (n = 42)* 
Baseline Leakage (n)  
No ≤5 g >5g Total 
Improved 
(No leakage) 
 
0 (0%) 
 
1 (2%) 
 
5 (12%) 
 
6 (14%) 
Improved 
(Leakage decreased to ≤5 g) 
 
0 (0%) 
 
0 (0%) 
 
13 (31%) 
 
13 (31%) 
Improved 
(Leakage decreased to >5 g) 
 
0 (0%) 
 
0 (0%) 
 
13 (31%) 
 
13 (31%) 
Not improved  
(No change/increased leakage) 
 
1 (2%) 
 
2 (5%) 
 
7 (17%) 
 
10 (24%) 
 
 
  
3 months 
Total 1 (2%) 3 (7%) 38 (90%) 42 (100%) 
Improved 
(No leakage) 
 
0 (0%) 
 
1 (2%) 
 
9 (21%) 
 
10 (24%) 
Improved 
(Leakage decreased to ≤5 g) 
 
0 (0%) 
 
0 (0%) 
 
7 (17%) 
 
7 (17%) 
Improved 
(Leakage decreased to >5 g) 
 
0 (0%) 
 
0 (0%) 
 
15 (36%) 
 
15 (36%) 
Not improved  
(No change/increased leakage) 
 
1 (2%) 
 
2 (5%) 
 
7 (17%) 
 
10 (24%) 
 
 
 
12 months 
Total 1 (2%) 3 (7%) 38 (90%) 42 (100%) 
 
* Data presented using last observation carried forward method. 
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Figure 1. Use of the Implacer (A-C). 
 
 
 
 
 
A  Assembled Implacer         B  Inserted into mid-urethra C Needle cover 
  with needles covered    retracted;needle 
   fixates the urethra 
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Figure 2. Median urine leakage as measured by (A) provocation test (95% confidence 
interval at baseline and 3, 6, and 18 months: 22 to 59, 2.0 to 24, 0.0 to 18, 2.0 to 22, 
respectively) and (B) median incontinence episodes in 24 hours after treatment (95% 
confidence interval at baseline, 3, 6, and 18 months: 1.7 to 3.1, 0.14 to 1.0, 0.29 to 
1.0, 0.14 to 0.71) with NASHA/Dx copolymer using the Implacer (n = 42). 
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Abstract 
Objective To investigate the effect on quality of life (QoL) of a novel system for 
stress urinary incontinence (SUI). 
Patients and methods In an open, prospective, multicentre study, 42 women 
not previously treated by  invasive therapy with urodynamically verified SUI received 
4 x 1.0 ml or 4 x 0.7 ml of non-animal stabilized hyaluronic acid/dextranomer 
copolymer injected transurethrally into the urethra via the Implacer™ device 
(Zuidex™ system, Q-Med AB, Uppsala, Sweden). QoL was assessed using the King’s 
Health Questionnaire. The patients’ perception of treatment benefit and the number of 
incontinence episodes/24 h were also investigated. 
Results There were significant improvements over baseline in seven of 10 
domains of the King’s Health Questionnaire at 3 months, and these improvements 
were sustained at 1 year. For the change from baseline to 1 year, eight of 10 domains 
showed a significant positive correlation with the number of incontinence episodes/24 
h. In terms of treatment benefit, most women perceived an improvement at 1, 3, 6 and 
12 months. Of the 18 women requiring re-treatment, most perceiving an improvement 
at 3, 6 and 12 months. 
Conclusions Treatment with the Zuidex system produced significant improvements 
over a year in both subjective QoL and objective incontinence measures, with a 
significant positive correlation observed between them. 
 
Keywords stress urinary incontinence, quality of life, questionnaires, 
NASHA/dextranomer copolymer 
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Introduction 
Stress urinary incontinence (SUI), i.e. ‘the complaint of involuntary leakage on effort 
or exertion, or on sneezing or coughing’,¹ is a common but often under-reported and 
under-treated condition, in which incidence rates increase with age.² However, SUI is 
not just a problem in middle-aged or older women, as high prevalence rates have also 
been reported in younger women (20–45 years old).3 SUI can have a severe impact on 
quality of life (QoL), and women with this condition have a significantly lower QoL 
than continent women.4, 5 The impact is multifactorial, affecting physical, social and 
psychological functioning and health perception, as well as in some cases sexual 
functioning, participation in employment, and sleep. Improving overall QoL should be 
the primary aim of all treatment for SUI. Current treatments include non-invasive 
therapy in the first instance (e.g. physiotherapy), sometimes supported by 
pharmacotherapy, with surgical therapy generally considered to be the next option in 
the many patients in whom these approaches fail. However, the majority of patients 
would choose not to have an operation for their incontinence,6 or it may be 
inappropriate. An alternative treatment option is endoscopic urethral injection, but this 
approach has gained limited acceptance because of concerns about both the safety and 
efficacy of previous bulking agents. 
A commercial copolymer is available, consisting of dextranomer microspheres (80–
250 µm) in a carrier gel of non-animal stabilised hyaluronic acid (Zuidex™, Q-Med 
AB, Uppsala, Sweden). Injecting this copolymer via a guiding instrument (the 
Implacer™, Q-med AB) is a minimally invasive treatment for SUI that can be 
administered as a hospital or an office procedure. Endoscopic injection of 
NASHA/Dx copolymer produced long-term efficacy (57% success rate; cure or 
improvement) in 20 SUI patients over a 6.5-year follow-up, with no long-term safety 
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concerns.7, 8 These findings are notable, given the relative difficulty of achieving cure 
in the study population (elderly, median 74.5 years, and the failure of both previous 
and subsequent treatments for SUI). NASHA/Dx copolymer has been shown to be 
effective and well tolerated in the endoscopic treatment of VUR in children, with 
efficacy persisting for at least 5 years, and no associated long-term adverse events.9 
The copolymer is the only injectable agent approved by the USA Food and Drug 
Agency for this indication; it is approved in European for the treatment of both VUR 
and SUI.  
The Implacer is a new hand-held device that unfolds and fixates the urethra (i.e. 
distends the urethral circumference, thus smoothing the longitudinal folds), to ensure 
symmetrical placement of the NASHA/Dx copolymer gel at four evenly spaced 
locations around the urethra. Injection of the copolymer via the Implacer showed 
promising efficacy in a 12-month study and was well tolerated. There were significant 
reductions in urine leakage by the provocation test and in the number of incontinence 
episodes/24 h, and these were sustained for at least a year.10 Given the importance of 
improving QoL in the treatment of SUI, the effect of treatment on QoL was also 
investigated in the 12-month study, and the results are presented here. 
 
Patients and methods 
Women aged ≥ 18 years (42, mean age 52.8 years, range 30.5-77.9) with SUI verified 
by leakage on coughing or a Valsalva manoeuvre, and with a history of SUI for at ≥ 1 
year, were treated in an open, prospective multicentre study.10 All the women had had 
no previous invasive therapy (i.e. no previous surgical therapy for SUI) and previous 
noninvasive treatment (e.g. behaviour modification, pelvic floor exercises, drug 
therapy) had failed. The study was conducted in accordance with the principles of the 
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Declaration of Helsinki and approved by independent ethical committees, with 
informed consent obtained from all participants.  
The patients were given 4 x 1.0 ml (32 women) or 4 x 0.7 ml (10 women) injections 
of NASHA/Dx copolymer using the Implacer (Zuidex™ system: four NASHA/Dx 
copolymer-filled syringes and the Implacer). After giving an appropriate anaesthetic 
and assembling of the Implacer, the four needles were covered with the Implacer tube 
and inserted into the urethra. The needle cover was retracted, allowing the four 
needles to move outwards at the mid-urethra. The four injections of copolymer were 
then given sequentially. Full information about the injection procedure is given 
elsewhere.10  
The impact of treatment on QoL was assessed using the King’s Health Questionnaire 
(KHQ),11 which patients completed at baseline, and at the 3- and 12-month follow-up 
visits. Translated and validated Swedish and Dutch versions were used, as the trial 
was conducted at centres in Sweden and The Netherlands.  
Data was obtained from 32 questions relating to the following domains: general health 
perceptions (one question); urinary symptoms (one question); role limitations, 
physical limitations, social limitations, personal relationships, emotions, sleep/energy, 
severity measures (19 questions); and incontinence impact (11 questions). The 
answers were scored on a 4-point scale, and took ≈ 10 minutes to complete. Summary 
scores in each domain range from 0 to 100, a higher value indicating greater 
impairment. The patients’ perception of treatment benefit was assessed at 1, 3, 6 and 
12 months after treatment. At the 1- and 3-month visits, patients were asked ‘Do you 
consider yourself improved regarding your incontinence problems since your last 
visit?’, with the response recorded as ‘yes’ or ‘no’. At the 6- and 12-month visits, the 
same question was asked again and an answer of ‘yes’ or ‘no’ requested. If the answer 
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was ‘no’ at the 1-month follow-up visit, one additional treatment could be 
administered 1–2 months after the first treatment, using the same method. If the 
answer was ‘no’ at the 3- or 6-month post-treatment visit, the patient was withdrawn 
because the treatment was ineffective and an alternative treatment prescribed. 
The number of incontinence episodes/24 h, as assessed by a 1-week micturition chart, 
were measured at baseline and the 1, 3, 6 and 12-month follow-up visits. 
Statistical analyses were based on the intention-to-treat and last observation carried 
forward principles. Median values are presented, as the data were not normally 
distributed. Changes from baseline in KHQ domain scores were analysed by 
Wilcoxon signed-rank test. Correlations between change from baseline to 12 months 
in KHQ domain scores and in the number of incontinence episodes/24 h were 
analysed using Spearman’s correlation coefficient test (one-sided). 
 
Results 
As the efficacy outcomes and the patient demographics were very similar for the 4 x 
1.0 ml and 4 x 0.7 ml groups, QoL variables were analysed for the total population 
only. At 3 months the median values of summary scores from seven of 10 KHQ 
domains were significantly lower than the baseline scores (Fig. 1): incontinence 
impact, role limitations, physical limitations (all p<0.0001), social limitations 
(p=0.0036), emotions, severity measures (p<0.001) and urinary symptoms 
(p=0.0019). Eight of 10 domains had no change in median scores between 3 and 12 
months, while severity measures increased from 33 to 40 and urinary symptoms 
decreased from 7 to 6. 
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At 12 months the median scores were significantly lower than baseline for 
incontinence impact, role limitations, physical limitations, social limitations, emotions 
(all p<0.001), severity measures (p=0.0029), and urinary symptoms (p=0.0021).   
For the three remaining domains (personal relationships, sleep/energy and general 
health perceptions), the median scores were the same at baseline, and 3 and 12 
months; for the first two of the three domains (personal relationships and 
sleep/energy) the median scores were zero at the three time.   
The median number of incontinence episodes/24 h decreased significantly between 
baseline and 12 months (p<0.0001).10 In terms of the change from baseline to 12 
months, eight of 10 KHQ domains had a significant positive correlation with the 
number of incontinence episodes/24 h (Table 1), while two domains did not (general 
health perception and social limitations).  
At 1, 3, 6 and 12 months, most patients perceived an improvement from the treatment 
(Fig. 2). The highest level of satisfaction was at 3 months (71%), with a slight 
decrease in the percentage of patients perceiving an improvement over the 9 months. 
Eighteen patients (43%) were re-treated because they had an insufficient response. Of 
these, 67%, 67% and 61% perceived an improvement at 3, 6 and 12 months, 
respectively, compared with 75%, 63% and 58% of patients receiving only one 
injection. 
 
Discussion 
This study assessed the effect on QoL of a novel treatment system for SUI; the 
measurement of QoL is particularly important in the area of urinary incontinence, 
given that it is largely a symptom-defined condition. QoL assessment is recommended 
by several committees and by the ICS,12-14 with patient- rather than clinician-based 
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questionnaires favoured 14; both generic (e.g. the Short-Form Health Survey 15) and 
disease-specific QoL questionnaires (e.g. the KHQ 11) are used. Many recent studies 
investigating treatment options for SUI have assessed the impact on QoL.16-20 The 
KHQ has been classified as ‘highly recommended’ for both men and women, based 
on published data confirming its validity, reliability and responsiveness to change,14 
and is simple to complete. In relation to the clinical significance of changes in domain 
scores, it is of relevance that there were significant correlations with common 
domains of the Short Form-36 questionnaire.11  
The present findings show that injecting NASHA/Dx copolymer via the Implacer 
produced significant improvements in QoL throughout the 12-month study. Although 
there was no change in three domains (personal relationships, sleep/energy and 
general health perceptions), SUI does not generally affect sleep, and the results 
relating to personal relationships should be treated with caution, as values for this 
domain were missing in nine patients at all visits. For most KHQ domains the 
subjective improvement in QoL correlated with objective improvement (fewer 
incontinence episodes/24 h).  
Importantly, the present data should be considered in context with patient preferences 
for the treatment of SUI. A recent survey of women with LUTS showed that most 
prefer less-invasive therapy, even if the chance of cure may be lower than with major 
procedures.6 The majority of women have realistic expectations of treatment outcome, 
with 43% hoping for a good improvement (reduced interference with daily life), and 
just 17% hoping for complete cure. Most women (65%) considered occasional 
leakage on coughing or sneezing to be acceptable after treatment. Treatment with 
NASHA/Dx copolymer via the Implacer is consistent with these attitudes, and is 
therefore likely to be viewed positively by many patients. The convenience of this 
  
Page 69 
treatment (quick, office-based procedure with rapid resumption of normal routine) 
may also be an important consideration. Consistent with the improvement in QoL, 
there were high levels of patient-perceived treatment benefit. This was also evident in 
women who had been re-treated (i.e. two injections), with the level slightly higher at 6 
and 12 months than in patients who had received one injection.   
The small deterioration in the percentage of patients perceiving an improvement from 
3 months onwards may be misleading, as the 3-month value is enhanced by patients 
then having a re-treatment. Reductions in urine leakage and the number of 
incontinence episodes/24 h were sustained over the 1-year period.10 Nevertheless, the 
follow-up of these patients will determine whether the decrease in perceived 
improvement will continue beyond a year, while further studies are awaited to 
determine whether this effect is real.  
The typical management of SUI progresses from non-invasive therapy to surgical 
procedures, with clinical guidelines stating that, as a general rule, the first choice 
should be the least invasive treatment with the fewest potential complications 
appropriate for the patient. For example, US Agency for Health Care Policy and 
Research guidelines state that behavioural and pharmacologic therapies are usually 
reasonable first steps in management.21 NASHA/Dx copolymer offers a minimally 
invasive active treatment that has the potential to fill the present gap between these 
options. Possible benefits include increased speed and convenience of active 
treatment, and availability to many more women than is currently the case, with fewer 
patients needing to undergo surgery. 
In conclusion, we describe a novel treatment for SUI that produces significant 
improvements over 12 months in both subjective QoL and objective incontinence 
measures, with a significant positive correlation observed between them.  
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TABLE 1. Spearman’s correlation coefficients between change from baseline to 12 
months in KHQ domain scores and in the number of incontinence episodes/24 h (All 
domains, 42 women, except personal relationships, 33, emotions, 41, and 
sleep/energy,  41). 
  
KHQ domain Correlation 
coefficient 
P 
General health perceptions  -0.12 0.8 
Incontinence impact  0.47 <0.001 
Role limitations  0.37 0.005 
Physical limitations  0.40 0.002 
Social limitations 0.21 0.09 
Personal relationships 0.37 0.02 
Emotions  0.44 0.002 
Sleep/energy  0.29 0.03 
Severity measures  0.44 <0.001 
Urinary symptoms 0.52 <0.001 
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FIG. 1. Effect of treatment with NASHA/Dx copolymer on KHQ domain scores at baseline (green), 3 (red) and 12 months (white). Seven of 10 
domains, except general health perceptions, personal relationships and sleep/energy, improved significantly. (All domains, 42 women, except 
personal relationships, 33, emotions, 41, and sleep/energy, 41).  
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FIG. 2.  The patients’ perception of treatment benefit at 1, 3, 6 and 12 months (improved, red; 
not improved, white). 
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Abstract 
Objectives To investigate the long-term efficacy, safety, and impact on quality of life 
(QoL) of stabilized non-animal hyaluronic acid/dextranomer (NASHA/Dx) gel (Zuidex™) – 
for the treatment of stress urinary incontinence (SUI). 
Methods This was an open, multicenter, prospective study of NASHA/Dx gel, in 42 
female patients aged ≥18 years, with SUI of undetermined pathophysiology (hypermobility 
and/or intrinsic sphincter deficiency).  Patients were followed for up to 36 months. Efficacy 
parameters included urine leakage by provocation test, number of incontinence episodes/24 
hours and patients’ perception of bladder condition. QoL was assessed using the King’s 
Health Questionnaire (KHQ). 
Results Seventeen patients completed the provocation test at 36 months: all were 
treatment responders (≥50% reduction in provocation test leakage) and nine were dry. For the 
intention-to-treat population (ITT), provocation test responder rate at 36 months was 41–66% 
(depending on statistical method used to substitute for missing values). At 36 months, 
significant reductions versus baseline were observed for the ITT population in both urine 
leakage by provocation test (6–14 vs. 37 g) and number of incontinence episodes/24 hours 
(0.6–1 vs. 1.9 episodes/day). Significant improvements were noted in six of the ten KHQ 
domain scores sustained to 36 months. At their last clinic visit, 26 patients (62%) reported 
improved perception of bladder condition. The majority of reported treatment-related adverse 
events was mild-to-moderate in severity and occurred within 12 months.  
Conclusions For patients remaining in this study, significant improvements in incontinence 
symptoms were observed up to 3 years post-treatment.  
 
Abbreviations: SUI, stress urinary incontinence; NASHA/Dx, stabilized non-animal 
hyaluronic acid/dextranomer; QoL, quality of life; KHQ, King’s Health Questionnaire 
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Introduction 
Stress urinary incontinence (SUI; involuntary leakage of urine upon exertion such as jumping, 
coughing or sneezing1) accounts for ≥50% of urinary incontinence cases reported by women.2 
Stabilized non-animal hyaluronic acid/dextranomer (NASHA/Dx) gel is a biocompatible and 
biodegradable material that, when injected into the urethra, augments the tissue helping to 
restore urinary continence.3 NASHA/Dx gel administered using the Implacer™ device is 
approved in Europe and currently under investigation in the USA for SUI.4,5 The Implacer is a 
novel, hand-held guiding instrument that provides a standardized transurethral injection 
method. The procedure does not require an endoscope or surgical facilities.  
The efficacy of NASHA/Dx gel for SUI was investigated in two open-label, multicenter, 
prospective studies.4,6 Statistically significant reductions in urine leakage were observed in 
both studies at 3 and 12 months post-treatment (p<0.0001 vs baseline, intention-to-treat [ITT] 
population).  Using the King’s Health Questionnaire (KHQ),7 both studies also showed that 
NASHA/Dx gel treatment produced significant improvements in quality of life (QoL).6,8  
Longer-term efficacy was demonstrated in a single cohort of elderly patients (using 
endoscopic urethral injection of NASHA/Dx gel, before introduction of the Implacer device), 
the majority of whom had failed previous SUI treatments.9 Of 16 patients followed up for 6–7 
years post-treatment, nine (56%) demonstrated a sustained response to treatment throughout 
follow-up.  
The present study was performed to assess the response in terms of urinary leakage and QoL 
up to 36 months post-treatment. 
 
Materials and methods 
This was an extension of an open, multicenter, prospective study of NASHA/Dx gel 
(Zuidex™; Q-Med, Uppsala, Sweden) for the treatment of SUI in females.4 The study was 
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approved by independent ethics committees and performed in accordance with the principles 
of the Declaration of Helsinki. A separate written consent form was signed by patients at  
12 months, for continuation with the study longer term.  
All patients were invasive-therapy naïve, aged ≥18 years, had a history of SUI for ≥12 months 
and had failed previous non-invasive treatments for SUI (e.g. pharmacotherapy, pelvic floor 
exercises, behavior modification). The presence of SUI was verified by demonstrable leakage 
on coughing or Valsalva maneuver. The pathophysiology of SUI (hypermobility and/or 
intrinsic sphincter deficiency) was not determined. Patients were excluded if they had a post-
void residual urine (PVRU) volume >100 ml or a mean volume voided <200 ml, urge 
incontinence, detrusor overactivity, recurrent urinary tract infection, were receiving 
medication for SUI, or were undergoing anticoagulant or immunosuppressive therapy. 
NASHA/Dx gel was administered using the Implacer device, under either general or local 
anesthetic. If following initial treatment the patient was not completely dry or improved to her 
satisfaction, one further treatment was offered after 1–2 months. The timing of subsequent 
follow-up visits (≥3 months) was taken from the last treatment received.  
Clinic visits for the initial study were scheduled at months 1, 3, 6 and 12. Patients that 
completed the 12-month follow-up were eligible to attend at 24 and 36 months. At all visits, 
the following assessments were made: urine leakage by provocation test (primary variable; 
short-term pad test using a standardized exercise routine with 300 ml saline in the bladder); 
number of incontinence episodes/24 hours (recorded in a patient diary); and patients’ 
perception of bladder condition (validated in patients with overactive bladder and 
recommended by the European Medicine Evaluation Association as a measure for urinary 
incontinence; graded as: no, some very minor, some minor, some, some severe, and many 
severe problems).4,10,11 A positive response to treatment was defined as a reduction in urine 
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leakage by provocation test of ≥50% from baseline. The KHQ was completed at months 3, 12, 
24 and 36.7  
Statistical analyses were performed on the results from all patients attending each study visit, 
and for the ITT population (i.e. all patients enrolled) at the final visit (36 months). Two 
analyses were performed on the ITT population: last observation carried forward (LOCF), and 
baseline value carried forward (BCF) techniques to substitute missing values. Intra-patient 
changes from baseline in urine leakage by provocation test, number of incontinence 
episodes/24 hours and median change from baseline in KHQ domain scores were analyzed by 
Wilcoxon’s signed rank test (two-tailed significance level of 0.05). Patients’ perception of 
bladder condition was analyzed using descriptive statistics. 
 
Results 
Forty-two patients were recruited at baseline (ITT population, Table I). Eighteen patients 
(43%) received a second treatment. 
Of 42 patients enrolled, 5 were lost to follow-up, 1 withdrew consent and 10 were withdrawn 
due to lack of efficacy during the first 12 months.4 Six patients were excluded at 12 months: 
re-treatment (1); treatment with tension-free vaginal tape (3); a move abroad (1); and site not 
participating in the extended period of the study (1). A further 2 patients were lost to follow-
up between 24 and 36 months: lack of efficacy and withdrew consent. Therefore, a total of 18 
patients remained at 36 months; one of whom was excluded from the provocation test 
assessments due to a negative result (0 g) recorded at baseline (false inclusion).  
Table II outlines results for patients attending each study visit up to 36 months. Of the 
seventeen patients who completed the final provocation test assessment all were treatment 
responders and 16 (94%) were classified as treatment responders at both the 3 month and 36 
month assessments. Nine patients attending at 36 months (53%) were dry: two (12%) were 
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dry at both 3 and 36 months. For the ITT population at 36 months (n=41), provocation test 
positive response rate was 41–66% (BCF and LOCF analyses, respectively) and 22–32% of 
patients were dry (no leakage (0 g) on provocation test). At each study visit, the majority of 
patients reported perceived improvements in bladder condition (intra-timepoint range 69–
83%). 
At 36 months, median urine leakage by provocation test in the ITT population decreased from 
37g at baseline to 6–14 g (p<0.0001), and the median number of incontinence episodes/24 
hours decreased from 1.9 at baseline to 0.6–1 (p≤0.0003). At all post-treatment visits, 
significant reductions versus baseline were observed in urine leakage by provocation test and 
number of incontinence episodes/24 hours (p<0.0001 vs baseline; Figs. 1 and 2).  
The KHQ domain scores for incontinence impact, role limitations, physical limitations, social 
limitations, emotions and urinary symptoms were significantly reduced from baseline to 36 
months in both ITT analyses (Table III). Similar outcomes were evident in results from 
patients attending each visit. Improvements in these domains were apparent at 3, 12 and 36 
months, with no evidence of deterioration during the follow-up period. A reduction in the 
score for the severity measures domain was also observed, but this did not reach significance 
at 36 months.  
The median domain scores for personal relationships and sleep/energy were zero at baseline 
(indicating no impairment) and did not increase at 3, 12 or 36 months. No significant change 
from baseline was observed in the general health perception domain score, either in the ITT 
analyses (36 months) or for the patients attending each visit.  
Treatment-related adverse events were reported in 36% (15/42) of patients. The majority 
(96%) were mild-to-moderate, and all occurred within 12 months.4 All, except one sterile 
abscess, were urinary system disorders, the most common being urinary tract infection (n=6), 
hematuria (n=4), urethral disorder (n=3) and decreased urine flow (n=3). 
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Discussion 
In this, the longest follow-up study of NASHA/Dx gel using the Implacer to date, 
improvements in incontinence symptoms were sustained for at least 36 months.  
A short-term pad test (provocation test) was chosen as the primary variable as it offers a 
standardized method of measuring incontinence severity (same bladder volume and exercise 
routine at each visit). 
To give a non-biased representation of the long-term response to treatment, two statistical 
analyses were applied to the ITT population. The first assumed all drop-outs were non-
responders, and substituted missing values with the value observed at baseline (baseline 
carried forward, BCF). The BCF analysis represents the “worst case”, as a proportion of drop-
outs may have achieved a long-term response, but discontinued the study for reasons 
unrelated to treatment (e.g. a move abroad).  The second analysis assumed that the value 
obtained at the final visit attended is maintained for all subsequent timepoints (last 
observation carried forward, LOCF). The LOCF analysis may represent a “best case”, as for 
some patients, treatment effect may not have continued after drop-out.  The LOCF analysis is 
a widely accepted method for substituting missing values in a dataset, used in previous studies 
of SUI treatments.4,12 Treatment outcome can be expected to lie somewhere between the BCF 
and LOCF values.  
For both ITT analyses, significant improvements in incontinence symptoms were observed at 
36 months (41–66% were treatment responders). For patients not responding to treatment, 
case reports have demonstrated that injection of NASHA/Dx gel does not affect later surgery 
for SUI if required.13 
The positive impact of NASHA/Dx gel treatment on QoL was also sustained to  
36 months. The greatest improvement was observed for those domains showing most 
impairment before treatment: incontinence impact, role limitations and physical limitations.  
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Direct comparisons of NASHA/Dx gel with other injectable materials are hampered by a lack 
of comparative studies. Nevertheless, available data suggest no clear difference in response 
rates between NASHA/Dx gel, collagen, calcium hydroxyapatite, carbon coated zirconium 
beads and silicone (3/4 patients cured or improved).14-17  
Comparing the long-term response of NASHA/Dx gel with other agents is also difficult due to 
lack of data and differences in study design (patient selection, assessments, definition of 
response). The results presented here are in agreement with a recent study of silicone 
(Macroplastique®) that demonstrated favourable long-term results (no significant difference in 
Stamey grading and objective cure rate between 6 and 60 months post-treatment).18 In 
contrast, a decline in effect over time has been observed with collagen, in particular, and 
carbon coated zirconium beads.14,17 The probability of remaining dry following collagen 
injection decreased from 71% to 46% at 1–3 years post-treatment in one study.19 In a later 
comparative study, efficacy rates decreased from 63% at baseline, to 21% and 9% at 36 
months for carbon-coated zirconium beads and collagen, respectively.20 The current 
observations with NASAH/Dx gel are of importance, therefore, given that NASHA/Dx gel, 
like collagen, is a biodegradable material. 
NASHA/Dx gel was well tolerated. The most frequent adverse events were of a type common 
to all substances following urethral injection (e.g. hematuria, and decreased urine flow).14 One 
patient in the original 12-month follow-up developed a pseudocyst – a rare potential 
complication following urethral injection, also reported in studies of alternative injectable 
agents including collagen and carbon coated zirconium beads.14,21 Investigations of 
NASHA/Dx gel for SUI have revealed a low overall incidence of pseudocysts (2–10%6,22) and 
cases can be easily resolved with simple fluid aspiration, performed as an outpatient 
procedure.5  
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Conclusions 
Injection of NASHA/Dx gel is well tolerated and improvements in incontinence symptoms 
are sustained in many patients for at least 36 months. These findings are encouraging and 
suggest that the Zuidex system (NASHA/Dx gel administered using the Implacer) is an 
appropriate treatment option for SUI where non-invasive methods have failed. 
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Figure 1. Median urine leakage by provocation test following treatment with NASHA/DX 
gel. Left-hand bars show results for the intention-to-treat population (n=41), using the 
baseline carried forward and last observation carried forward methods, respectively, for 
substituting missing values at 36 months. Right-hand bars show results for patients attending 
each study visit.  
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Figure 2. Median number of incontinence episodes/24 hours following treatment with 
NASHA/DX gel. Left-hand bars show results for the intention-to-treat population (n=42) 
using the baseline carried forward and last observation carried forward methods, respectively, 
for substituting missing values at 36 months. Right-hand bars show results for patients 
attending each study visit.  
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Table 1. Baseline characteristics of the ITT study population (n=42) 
Mean age, years (range) 
Mean body mass index, kg/m2 (range) 
Menopause, n (%) 
Deliveries 0–2, n (%) 
Deliveries 3–4, n (%) 
Duration of symptoms >5 years 
Severe problems (patient perception)* 
Previous non-drug therapy for SUI 
53 (78-30) 
24.4 (34.3-19.0) 
22 (52%) 
29 (69%) 
13 (31%) 
33 (79%) 
22 (52%) 
42 (100%) 
Urine leakage by provocation test, g (median [range]) 
Number of incontinence episodes/24 hours (median [range]) 
Maximum urethral closure pressure, cm H20 (mean [range]) 
Maximum cystometric capacity, ml (mean [range]) 
35.5 (300-0) 
1.9 (24-0) 
44 (86-9) 
473 (960-170) 
*A report of ‘some severe’ or ‘many severe’ problems on the six-point patients’ perception of 
bladder condition scale. 
 
 
Table II. Treatment responders*, patients dry (no leakage) and patients showing an 
improvement of at least one category on the patients’ perception of bladder condition scale  
 36-month efficacy  
(ITT population) 
Observed efficacy at each study visit attended 
(month) 
Assessment BCF 
analysis 
LOCF 
analysis 
1 3 6 12 24 36 
Provocation test 
responder rate* 
17/41§ 
(41%) 
27/41§ 
(66%) 
24/40 
(60%) 
25/38 
(66%) 
25/27 
(93%) 
20/24 
(83%) 
16/19 
(84%) 
17/17 
(100%) 
Patients dry  
(no leakage (0 g) 
on  provocation 
test) 
9/41§ 
(22%) 
13/41§ 
(32%) 
8/40 
(20%) 
5/38 
(13%) 
13/27  
(48%) 
6/24 
(25%) 
6/19 
(32%) 
9/17 
(53%) 
Patients reporting 
improved 
perception of 
bladder condition 
15/42 
(36%) 
26/42 
(62%) 
30/42 
(71%) 
27/39 
(69%) 
22/27 
(81%) 
20/25 
(80%) 
15/20 
(75%) 
15/18 
(83%) 
*A response is defined as a ≥50% reduction from baseline in urine leakage by provocation 
test.  
§One patient was excluded from provocation test assessment due to false inclusion. 
ITT: intention to treat. BCF: baseline carried forward. LOCF: last observation carried forward 
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Table III. Effect of treatment with NASHA/Dx gel on King’s Health Questionnaire domain 
scores 
 Median change from baseline in 
domain score at 36 months  
(ITT population) 
Median change from baseline in 
domain score at each study visit 
attended  
Domain BCF analysis 
 (n) 
LOCF analysis 
 (n) 
3 months 
 (n) 
12 months 
 (n) 
36 months 
 (n) 
General 
health 
perception 
0 (42) 
p=0.29 
0 (42) 
p=0.21 
0 (39) 
p=0.68 
0 (25) 
p=1.0 
0 (17) 
p=0.29 
Incontinence 
impact 
0 (42) 
p=0.0006 
-33 (42) 
p<0.0001 
-33 (39) 
p<0.0001 
-33 (24) 
p<0.0001 
-33 (17) 
p=0.0006 
Role 
limitations 
0 (41) 
p=0.0004 
-17 (41) 
p< 0.0001 
-17 (38) 
p<0.0001 
-17 (24) 
p=0.0002 
-33 (16) 
p=0.0004 
Physical 
limitations 
0 (42) 
p=0.0001 
-17 (42) 
p<0.0001 
-33 (39) 
p<0.0001 
-33 (25) 
p<0.0001 
-33 (17) 
p=0.0001 
Social 
limitations 
0 (41) 
p=0.01 
-11 (41) 
p=0.0006 
-11 (38) 
p=0.004 
-11 (24) 
p=0.0004 
-11 (16) 
p=0.01 
Personal 
relationships 
0 (31) 
p=1.0 
0 (31) 
p=0.11 
0 (29) 
p=0.23 
0 (16) 
p=0.55 
0 (8) 
p=1.0 
Emotions 0 (41) 
p=0.005 
-11 (41) 
p=0.006 
-11 (38) 
p<0.0001 
-11 (25) 
p=0.006 
-11 (16) 
p=0.005 
Sleep/energy 0 (41) 
p=0.53 
0 (41) 
p=0.03 
0 (38) 
p=0.009 
0 (25) 
p=0.01 
0 (17) 
p=0.53 
Severity 
measures 
0 (42) 
p=0.13 
-7 (42) 
p=0.03 
-10 (38) 
p=0.0005 
-13 (25) 
p=0.01 
-7 (17) 
p=0.13 
Urinary 
symptoms 
 
0 (42) 
p=0.002 
-1.0 (42) 
p=0.005 
-2 (37) 
p=0.002 
-4 (24) 
p=0.006 
-2 (17) 
p=0.002 
ITT: intention to treat. BCF: baseline carried forward. LOCF: last observation carried forward 
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Abstract 
Objective: To assess the efficacy of silicone microimplants (Macroplastique®; 
polydimethylsiloxane) therapy for stress urinary incontinence in adult women, using a 
systematic review of identified studies. 
Materials and methods: A computer-aided and manual search for published studies 
investigating silicone microimplants therapy for stress urinary incontinence in adult women. 
The methodological quality of the included studies was assessed using criteria based on 
generally accepted principles of interventional research.  
Results: Only two RCTs, only published as an abstract, were found. Eleven pre-experimental 
or observational studies were identified. Overall, the methodological quality was low. The 
main methodological shortcomings of the studies were no random allocation procedure, lack 
of prestratification on prognostic determinants, no blinding, small sample sizes, and lack of 
proper analysis and presentation of results. There was variability in the indication for 
implantation, implantation procedure, rate and volume of silicone microimplants. The use of 
different outcome measures in most of the trials made comparison between studies difficult.  
Conclusions: Because of the low methodological quality of included studies, results should 
be interpreted with caution and no firm conclusions about the efficacy of silicone 
microimplants were possible. Randomized clinical trials, using valid and reliable subjective 
and objective measurements, are necessary to establish the efficacy of silicone microimplants 
therapy in treating stress urinary incontinence in adult women.  
Key words: Macroplastique; silicone microimplants; injectable; urethral bulking agent; 
polydimethylsiloxane; stress urinary incontinence; adult; woman. 
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Introduction 
Urinary incontinence is a common but often neglected condition. The prevalence of urinary 
incontinence increases with age; 10-25% of women under age 65, 15-30% of women in the 
community, and more than 50% of nursing home residents are affected by this condition (1). 
Stress urinary incontinence is a major contributor to urinary incontinence with an estimated 
prevalence of 21-46% (2,3). It is characterized by the involuntary leakage of urine, when the 
intra-vesical pressure exceeds the urethral resistance as a result of increased intra-abdominal 
pressure in the absence of a detrusor contraction (4). The treatment of an incontinent patient 
should be offered sequentially, beginning with the least invasive therapy. Treatment options 
are physiotherapy, minimally invasive devices, pharmacotherapy, urethral injections and 
surgery.  
The basic principle of endoscopic injection of bulk-enhancing agents for treating stress 
urinary incontinence is the provision of an additional submucosal bulk. The bulking agent is 
usually implanted submucosally in the area of the bladder neck (mid-urethra) in women and at 
the external sphincter in men, and acts as a bulking agent which augments the urethral 
mucosa, improves coaptation and intrinsic sphincter function, resulting in an increase of 
urethral closing pressure and restoring urinary incontinence.  
For many years various injectables or urethral bulking agents have been used in treating 
female stress urinary incontinence. In 1938, Murless produced the first report after injection 
of a sclerosing solution (sodium morrhuate) into the anterior wall of the vagina of 20 
incontinent women, obtaining temporary scarring of the juxtaurethral tissues (5). In 1955, 
Quackels described 2 cases treated with paraffin injection into the perineum with restoring 
continence by compression of the membranous urethra (6). In 1963, Sachse described the use 
of the sclerosant Dondren into the urethra with some success (7). Local tissue damage and 
pulmonary complications, including pulmonary infarction and emboli, restricted continuation 
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of their use. In the early seventies, Berg (8) and Politano (9) first described the use of 
polytetrafluoroethylene (PTFE : Teflon) injections around the urethra. In 1989, 
glutaraldehyde cross-linked collagen and autologous fat were first described by Shortliffe (10) 
and Gonzales de Garibay (11), respectively. The efficacy and disadvantage(s)/side-effect(s) of 
these injectables or urethral bulking agents are presented in Table 1 (12-35).  
Ideally, a bulking agent should be non-immunogenic, biocompatible, non-toxic, and hypo-
allergenic. Moreover, a bulking agent should be effective and demonstrate anatomical 
integrity, bonds to local tissues with minimal inflammation, keeps its injected volume, does 
not migrate to vital organs, should be easy to use and be cost-effective.  
The injectable agent, Macroplastique® (Uroplasty BV, Geleen, the Netherlands), is described 
as a solid silicone elastomer with favorable biocompatibility and bulking properties and 
meets, according to the manufacturer (36), the criteria mentioned above. In this report, we 
performed a systematic review to assess both this statement and its efficacy, and to evaluate 
procedures and possible side-effect(s) of silicone microimplants for the treatment of stress 
urinary incontinence in adult women. 
Macroplastique®, the material 
Macroplastique® is a soft tissue bulking agent and is comprised of soft, flexible, highly-
textured irregularly-shaped implants of heat vulcanized polydimethylsiloxane (a solid silicone 
elastomer) suspended in a bio-excretable carrier gel. The carrier gel is a pharmaceutical grade, 
water-soluble, low molecular weight polyvinylpyrrolidone (PVP or povidone) hydrogel which 
is absorbed by the reticuloendothelial system and excreted unchanged in the urine. 
Polydimethylsiloxane elastomer and polyvinylpyrrolidone have favorable biocompatibility 
properties. Polydimethylsiloxane is well tolerated by the cellular immune system and is non-
genotoxic, non-carcinogenic and non-teratogenic (36). Nowadays, there is still some 
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discussion about the minimal particle-size of urethral bulking agents with respect to 
migration, but authors seem to agree that particles larger than 80 µm are not likely to migrate 
(37). In relevant literature, particle-sizes of  polydimethylsiloxane varied between 120 – 264 
µm (38, 39). 
Because of its irregular shape and textured surface, agglomeration and host collagen 
deposition will be enhanced and encouraged.  Injected particles will be organized within 6 to 
8 weeks in firm nodules with infiltrated collagen and surrounded by a fibrous sheath that is 
well developed at 9 months (37, 40-42). Therefore, the risk of biodegradation and migration 
of polydimethylsiloxane appear to be non-existing (38). Because of the good bulking 
characteristics of polydimethylsiloxane mentioned above, probably less material has been 
required compared to other injectable bulking agents. 
The safety of solid polydimethylsiloxane is demonstrated by its long history of successful use 
in different kinds of biomedical devices, like catheters, etc. There are reports showing an 
association between silicone gel-containing breast implants and late-onset connective tissue 
disorders (43-45). However, polydimethylsiloxane is a solid elastomer and not a silicone gel. 
No evidence has been reported that elastomers are associated with connective tissue disease 
(46). 
Macroplastique®, the procedure 
The endoscopic injection procedure can be performed under general, regional or local 
anesthesia. During the transurethral procedure, under direct cystoscopic vision the needle is 
placed submucosally into the urethra at the six, ten and two o’clock positions 1.5 to 2.0 cm 
distal from the bladder neck. The material is slowly injected until a sufficient mucosal bleb is 
achieved. The procedure is completed if there is a total mucosal apposition together with 
occlusion of the urethral lumen. The injectable can also be administered periurethrally. This 
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procedure is performed under cystoscopic control by inserting a spinal needle percutaneously 
adjacent to the urethra. After injecting, the cystoscope should not be advanced past injected 
areas and only small ‘in and out’ catheters (8-12 Fr) should be inserted because this may 
result in compression or extrusion of the bulking agent afterwards. To improve and simplify 
the transurethral implantation technique and to minimize problems associated with 
endoscopic procedures, the Macroplastique Implantation System (MIS) was developed for the 
treatment of female stress urinary incontinence. The device seems to allow a constant 
placement of the implants at predefined depth and angles at the six, ten and two o’clock 
position of mid-urethra within the same circumferential plane. To identify the site of 
implantation correctly, the ruler measuring scale on the topside of the device is used. The site 
of the bladder neck is identified as the position where the water flow from the fluid drainage 
channel ceases while the tip of the device is slowly withdrawn from the fluid-filled bladder. 
The standard implantation position is defined by withdrawing the device from the urethra to 
the appropriate location of the mid-urethra, i.e., 10-15 mm distance from the level of the 
bladder neck (Fig. 1).  
 
Materials and methods 
The computerized bibliographic databases from Medline, Excerpta Medica and Cochrane 
Field in Therapies and Rehabilitation at the University of Maastricht were searched for 
randomized clinical trials (RCTs), controlled clinical trials (CCTs), and studies with a pre-
experimental or observational design, published between 1980 and 2002. The keywords 
incontinence, urinary incontinence, stress urinary incontinence, genuine stress incontinence, 
urethra, injection, injectable, bulking agent, Macroplastique, silicone microimplants, adult and 
woman were used. Manual searches for more references of this literature were also 
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undertaken. Selection criteria were used for inclusion of studies in this systematic review, and 
are listed in Table 2.  
The methodological quality of the studies was assessed using a modified list of predefined 
methodological criteria, the Maastricht-Amsterdam Consensus List (47,48), based on 
generally accepted principles of interventional research (49,50). These criteria assess the 
internal validity (criteria B, E, F, G, H, I, J, L, N, P), external validity (criteria A, C, D, K, M), 
and power (criteria O, Q) (see Table 3). Points were given to each fulfilled criterion, and zero 
if not. The maximum methodological quality score (MQS) was 100 points. Because the two 
independent reviewers (PhHtM, LCMB) were familiar with most included studies, there was 
no blinding for authors, journals, and institution during assessment. After assessment, a 
hierarchical MQS list was generated; a higher MQS indicated that a study had a higher 
methodological quality. Studies were classified as of ‘sufficient’ methodological quality (i.e. 
moderate to high quality studies scoring ≥ 50 points) or ‘low’ quality. Low-quality studies 
provide more limited evidence for efficacy of a treatment, because systematic errors or bias is 
more likely and more difficult to prevent (51).  
 
Results 
The literature search yielded 13 manuscripts (52-66) and 37 abstracts. Two manuscripts were 
excluded because they were published in different languages and no version in any of the 
languages mentioned above was available (63,64). Only two RCTs were found.  Because 
these were published only as an abstract, they had to be excluded (65,66). Five manuscripts 
were pre-experimental and observational prospective studies (54,57-59,62), the other six were 
considered to be retrospective (52,53,55,57,60,61). In Table 4, the 11 studies are presented in 
a hierarchical order according to the MQS; the median (range) MQS was 26 (21-34) from the 
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maximum of 100 points. Of the methodological quality criteria, 14 of the 20 (A1, B1, B2, C, 
D, E, F, G, H, I, L, N, O, Q) were met by < 60% of the studies. The main methodological 
shortcomings of the studies were no random allocation procedure, lack of prestratification on 
prognostic determinants, no blinding, small sample sizes, and lack of proper description of 
analysis and presentation of results. Only 5 studies had a description of the inclusion and 
exclusion criteria (54,57,60-62). None of studies were of sufficient methodological quality to 
enable valid conclusions to be drawn about polydimethylsiloxane injection for treating stress 
urinary incontinence due to intrinsic sphincter deficiency or urethral hypermobility in adult 
women.  
The results of the studies are summarized in Table 5. Three different implantation procedures 
of polydimethylsiloxane were performed; periurethral (52,56,61,62), transurethral (53-55,58-
60), or with the use of MIS (57). The indication for implantation was stress urinary 
incontinence due to intrinsic sphincter deficiency with or without urethral hypermobility. A 
subgroup analysis was performed in two studies (58,62). In two other studies the type of 
stress incontinence was not mentioned (52,57). In all studies, most of the patients had 
undergone previous anti-incontinence or prolapse surgery. The procedure was performed 
under local, regional, or general anesthesia. The average implantation rate and volume were 
different between the studies, and varied between 1-1.47 and 2-7 ml, respectively. A second 
injection after 3 months was performed in some of the patients in an attempt to upgrade the 
outcome to dry (52-54,56-61). Reported cure and success rates (cured and improved) using 
polydimethylsiloxane for only intrinsic sphincter deficiency varied between 14 and 66.7% and 
between 46 and 80%, respectively. For intrinsic sphincter deficiency with urethral 
hypermobility, the cure and success rates varied between 0 and 21.4% and between 0 and 
58.9%, respectively. Follow-up of the studies varied between 3 months and 3 years. Follow-
up showed decreased success rate in 6 studies (52-56,62). Outcome measurements of the 
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studies were either subjective or objective, or both. Results were measured subjectively by 
rating of the investigator or using a patient questionnaire (53,55-58,60,62). In 4 studies the 
results were also assessed objectively using a stress test or urodynamic studies (52,54,59,61).  
At 6 and 12 months after polydimethylsiloxane injection, the maximum urethral closure 
pressure at rest increased significantly in 2 studies (54,56). In another study, urodynamics 
showed a significant increase in functional urethral length, although no change in maximum 
urethral closure pressure at 1 month follow-up (58). Most of the failures were associated with 
vesical descent or bladder neck hypermobiltiy (53,58,62). Before treatment there was no 
difference between women with or without mild cystocele (55,56). Two studies reported after 
injection “de novo” idiopathic detrusor overactivity (52,59).  
In one study the MIS was described (57). Operator acceptance of this procedure was excellent 
or acceptable in 95% after first treatment and 100% after re-treatment. Urethral insertion was 
rated as acceptable in 92.5% of the procedures. In 89% of the implantation procedures, mild 
or moderate pain was experienced. All injections were performed under local anesthesia, 
except for 2 patients who wanted general anesthesia during re-treatment. 
None of the studies reported major complications during or after the procedure. Only minor 
and transient complications, including dysuria, frequency, hematuria, post-operative pain, and 
urinary retention requiring intermittent catheterisation, have been described. 
 
Discussion 
Because in this systematic review only studies on silicone microimplants (Macroplastique®; 
polydimethylsiloxane) are reviewed, any possible financial support or contribution of the 
manufacturers to the design or statistical analysis was investigated. It appeared to be that only 
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support from the part of the industry was related to the provision of free material in two 
studies (52,57). 
To our knowledge, this is the first published systematic review of silicone microimplants 
therapy for stress urinary incontinence in adult women that used a list of criteria to assess the 
methodological quality of included studies. Because of the poor methodological quality and 
shortcomings and the variability in patient selection and interventional design, comparison 
between studies was difficult. Therefore, results should be interpreted with caution and no 
firm conclusions about the efficacy of silicone microimplants were possible. Lack of 
methodological quality still is a general problem in most studies investigating effects of 
bulking agents for stress urinary incontinence in adult women. A problem also faced in all 
other kinds of treatments.  Therefore societies like the International Continence Society (ICS), 
American Urologic Association (AUA) and the World Health Organization (WHO) are 
developing methodological guidelines for research.   
Careful patient selection by optimal diagnostical tools, like history taking including quality of 
life questionnaires, detailed physical examination, pad test, urodynamic assessment, bladder 
neck excursion measurements and review of a frequency/volume chart is important for 
maximal results of urethral bulking agent therapy. Urodynamic evaluation is necessary to 
demonstrate reduced leak point pressure and to exclude detrusor overactivity and bladder 
compliance abnormalities.  
In general, injection therapy with urethral bulking agents is considered by patients and 
surgeons as a minimally invasive procedure. Injectables are suggested to offer several 
potential advantages over other surgical procedures, including lower morbidity, shorter 
procedure time, shorter inpatient stay and more rapid recovery (67). The procedure is most 
commonly based on day-case care and use of local or regional anesthesia.  
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The mechanism of restoring continence after successful injection therapy is still not clear. 
Radley et al. reported that firm nodules were realized 6 weeks after polydimethylsiloxane 
implantation subserosally in the proximal urethra. These findings suggest that the mechanism 
of action of polydimethylsiloxane is augmentation of pressure transmission to the proximal 
urethra by producing focal and firm expansion of periurethral tissues (41). In some studies an 
obstructive component with a decrease in maximum flow and an increase in maximum 
detrusor pressure has been reported (30,68,69). Other authors have suggested that obstruction 
is not the mechanism of restoring continence (29,58,70,71). In successfully treated patients, 
injections result in a cephalad elongation of the urethra with a concomitant increase in 
pressure transmission ratio in the first quarter of urethral length. These changes are due to 
adequate injection at the bladder neck or proximal urethra preventing bladder neck opening 
during stress (29,58,70,71). Therefore, exact placement of the injection material is important 
to achieve continence. An endoscopic procedure seems to be superior to periurethral 
application or ultrasound-guided injection for treating incontinence (72). As a procedure, MIS 
is a more easy procedure to perform than endoscopically guided implantation. The device 
enables consistent bolus placement at a pre-determined depth and site (57). Radley et al 
reported in general success to be associated with complete encirclement of the urethra by 
polydimethylsiloxane (59). If polydimethylsiloxane treatment failed, transvaginal or 
transurethral ultrasound could be performed to investigate correct placement of 
polydimethylsiloxane. 
In general, optimal patient selection for injection therapy seem to be elderly women, patients 
with high operative risk, refuse open surgery, those following multiple previous pelvic 
surgery and radiotherapy, or those with stress incontinence due to intrinsic sphincter 
deficiency (70). Injection therapy might also be a good option for those women who want 
pregnancy/delivery. Patients with stress incontinence, caused by a combination of urethral 
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hypermobility and intrinsic sphincter deficiency, with failure of suspension, may also benefit 
from this procedure (70). Bladder neck hypermobility may decrease the success of injection 
therapy (53,58,62,73). However, some studies have reported a positive outcome of 
periurethral collagen injections in patients with stress incontinence caused by urethral 
hypermobility (30,74). In other studies no differences in success between stress urinary 
incontinence with and without urethral hypermobility could be found (28,75,76). Success 
seemed to be independent of age, parity, previous pelvic surgery, severity of incontinence, or 
concomitant a small or mild cystocele (52,53,55,56). However, patients with no previous anti-
incontinence surgery seemed to have subjectively and objectively superior results in 
comparison with patients after previous anti-incontinence surgery (59). It is likely, that pre-
existent and ‘de novo’ idiopathic detrusor overactivity are negative prognostic factors for 
success. Patients with gross pelvic organ prolapse are not suitable for injection therapy (77). 
A leak point pressure increase of 10 cm H2O or more may predict success of therapy, 
providing indication of restoring continence and the required amount of injection material 
(78). Patients with a maximum urethral closure pressure of 20–50 cm H2O at rest had a better 
outcome than patients with a maximum urethral closure pressure lower than 20 cm H2O (79).  
As previous polydimethylsiloxane implantation does not appear to compromise future 
surgical outcome, patients who do not respond to injection therapy may still be treated using 
open surgical techniques (80). 
Further research is mandatory to improve patient selection for treatment with urethral bulking 
agents. Treatment needs to be cost-effective since only limited resources are available for 
general healthcare.  
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Conclusions  
Because of the low methodological quality of included studies, results should be interpreted 
with caution and no firm conclusions about the efficacy of silicone microimplants were 
possible. Randomized controlled clinical trials, using valid and reliable subjective and 
objective measurements, are necessary to establish the efficacy of silicone microimplants 
therapy in treating stress urinary incontinence in adult women. 
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  Fig. 1.  The Macroplastique Implantation Device (MID) 
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Table 1. The efficacy and disadvantage(s)/side-effect(s) of other urethral bulking agents than Macroplastique® in treating stress urinary 
incontinence in adult women 
  
Material Efficacy*     Disadvantage(s)  Side-effect(s)      
 
FU: 2-6 months 12-60 months             
 
Teflon  50-86%  18-54%  difficult procedure(12), bladder outlet obstruct on, urethral scarring  
      allergic reaction (12)  due to fibrosis (13), 
granuloma formation at injection site (14), distant 
migration to lymf nodes, lung, kidney, brain, spleen 
(14,15), 
para-urethral abscess, urethral diverticulum, granuloma 
with urethral prolapse (16),  
carcinogenic potential (17,18).   
     
Collagen 80-100%  57-95%  expensive, refrigeration overall complication rate of 20%: ‘de novo’  
required, rapidly absorbed, urgency, hematuria, urinary retention and  
repeated injection,  delayed skin reaction associated with  
preinjection skin testing, arthralgia (20), periurethral pseudocyst (21), 
allergic reaction; 4% (19) urethral prolapse (22), osteitis pubis (23),  
    time-dependent decrease of efficacy (24-30). 
   
Autologous fat    23-65%** tissue harvesting,  time-dependent decrease of efficacy (31), 
rapidly absorbed,  one death has been attributed to fat 
repeated injection (31) embolization(32),urethral pseudolipoma(33) connective 
tissue replacement (34). 
 
* Effect of an injectable or urethral bulking agent is defined as the total success rate consisting of both cure and improvement rates (34,35). 
** FU = follow-up : 6-30 months.             
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Table 1. The efficacy and disadvantage(s)/side-effect(s) of other urethral bulking agents than Macroplastique® in treating stress urinary 
incontinence in adult women 
  
Material Efficacy*     Disadvantage(s)  Side-effect(s)      
 
FU: 2-6 months 12-60 months             
 
Teflon  50-86%  18-54%  difficult procedure(12), bladder outlet obstruct on, urethral scarring  
      allergic reaction (12)  due to fibrosis (13), 
granuloma formation at injection site (14), distant 
migration to lymf nodes, lung, kidney, brain, spleen 
(14,15), 
para-urethral abscess, urethral diverticulum, granuloma 
with urethral prolapse (16),  
carcinogenic potential (17,18).   
     
Collagen 80-100%  57-95%  expensive, refrigeration overall complication rate of 20%: ‘de novo’  
required, rapidly absorbed, urgency, hematuria, urinary retention and  
repeated injection,  delayed skin reaction associated with  
preinjection skin testing, arthralgia (20), periurethral pseudocyst (21), 
allergic reaction; 4% (19) urethral prolapse (22), osteitis pubis (23),  
    time-dependent decrease of efficacy (24-30). 
   
Autologous fat    23-65%** tissue harvesting,  time-dependent decrease of efficacy (31), 
rapidly absorbed,  one death has been attributed to fat 
repeated injection (31) embolization(32),urethral pseudolipoma(33) connective 
tissue replacement (34). 
 
* Effect of an injectable or urethral bulking agent is d fined as the total success rate consisting of both cure and improvement rates (34,35). 
** FU = follow-up : 6-30 months.             
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Table 2. Selection criteria for inclusion of studies in this systematic review. 
1. The design was either a RCT, or a CCT, or a study with a pre-experimental or 
observational design. 
2. Adult women with stress urinary incontinence due to intrinsic sphincter deficiency or 
urethral hypermobility, or both. 
3. The treatment of stress urinary incontinence was transurethral or periurethral 
Macroplastique injection. 
4. The study was published in English, German, French, or Dutch. 
5. Abstracts and unpublished studies were excluded. 
 
Table 3. Criteria for assessing methods in studies of the efficacy of Macroplastique® for 
stress urinary incontinence in adult women using the Maastricht-Amsterdam Consensus List 
(47,48). 
 
Criteria       Answer options points 
Patient selection 
A. About the specification of the eligibility criteria: 
1 Were the inclusion and exclusion criteria described? Yes/No/Don’t know  2 
2 Is the diagnostic procedure described?   Yes/No/Don’t know  4 
B. Treatment allocation  
1 Was a method of randomization performed?  Yes/No/Don’t know 10 
2 Was the treatment allocation concealed?   Yes/No/Don’t know 5 
C. Were the groups similar at baseline regarding the Yes/No/Don’t know 6 
   most important prognostic indicators?  
Interventions 
  
Page 116 
D. Were the index and control interventions explicitly Yes/No/Don’t know 10 
   described? 
E. Was the care provider blinded to the intervention? Yes/No/Don’t know 4 
F. Were co-interventions avoided or comparable?  Yes/No/Don’t know 4 
G. Was the compliance acceptable in all groups?  Yes/No/Don’t know 4 
H. Was the patient blinded to the interventions?  Yes/No/Don’t know 4 
Outcome measurement 
I. Was the outcome assessor blinded to the intervention? Yes/No/Don’t know 4 
J. Were the outcome measures relevant?   Yes/No/Don’t know 8 
K. Were adverse effects described?    Yes/No/Don’t know 1 
L. Was the withdrawal/dropout rate described and  Yes/No/Don’t know 8 
   acceptable? 
M. Timing of follow-up measurements 
1. Was a short term follow-up measurement performed? Yes/No/Don’t know 3 
2. Was a long term follow-up measurement performed? Yes/No/Don’t know 2 
N. Was the timing of the outcome assessment in both Yes/No/Don’t know 4 
   groups comparable? 
Statistics 
O. Was the sample size for each group described and  Yes/No/Don’t know 11 
   adequate? 
P. Did the analysis include an intention-to-treat analysis? Yes/No/Don’t know 4 
Q. Were point estimates and measures of variability Yes/No/Don’t know 2  
   presented for the primary outcome measures?  
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Table 5. Study results of Macroplastique® implants for stress urinary incontinence in adult women 
 
Reference N Type GSI Previous 
anti- 
incontinence 
surgery 
Average 
implantation 
rate (n) 
Average 
volume 
(ml) 
Retreatment 
(n) 
Outcome 
measures 
(Subj/Obj) 
Cured 
% (n) 
Improved 
% (n) 
Failed 
% (n) 
Lost to 
follow-up 
Average  
follow-up 
months 
(range) 
Side-effects 
% (n) 
Gurdal 
(62);2002 
15 
14 
ISD 
ISD/HU 
18 1 3.5 0 Subj 66.7 (10) 
21.4 (3) 
13.3 (2) 
13.3 (2) 
20.0 (3) 
64.3 (9) 
0 24 44.8 (13) hematuria, 
79.3 (23) dysuria, 
72.4 (21) frequency, 
3.4 (1) retention 
Peeker 
(61);2001 
22 ISD 22 1.32 NS 7 Subj+Obj 59.1 (13) 18.2 (4) 22.7 (5) 0 - (6-48) Practically all 
patients dysuria, few 
had initial sensation 
of incomplete 
bladder emptying 
Soliman 
(60);2001 
68 ISD 14 1.07 3 5 Subj 35.2 (24) 26.5 (18) 38.2 (26) 0 19 (3-32) 5.9 (4) retention 
Radley 
(59);2001 
60/56 
     41 
ISD/HU 41 1.47 6.73  28 Subj 
Obj 
19.6 (11) 
39 (16) 
39.3 (22) 
 
41.1 (23) 
43.9 (18) 
0 19(6-50) 
16(6-52) 
12.3% (11)retention, 
5.6% (6) UTI 
Barranger 
(58);2001 
21 
6 
ISD 
ISD/HU 
21 1 4 2 Subj 19 (4) 
0 
29 (6) 
0 
52  (11) 
100 (6) 
0 31 
(24-34) 
NS 
Henalla 
(57); 
2000 
40 NS 28 1.35 6.8 19 Subj 41 (16) 33.3 (13) 25.7 (10) 1 6 17.5 % (7) retention, 
63.3% (25) 
hematuria 
and dysuria, 
89% (49/55) mild/ 
moderate pain 
during injection 
Hidar  
(56);2000 
25/15 ISD 16 1.47 3.7 8 Subj 33 (5) 27 (4) 40 (6) 10 36 8% (2) retention 
 
Usman 
(55);1998 
71  
31  
ISD (p) 
ISD (s) 
- 1 5 0 Subj 30 (21) 
42 (13) 
37 (26) 
29 (9) 
34 (24) 
29 ((9) 
0 3.2 
(3-5) 
6.8% (7) retention, 
1%  (1) UTI 
Usman 
(55);1998 
56  
28  
ISD (p) 
ISD (s) 
- 1 5 0 Subj 23 (13) 
14 (4) 
25 (14) 
32 (9) 
52 (29) 
54 (15) 
0 17.6  
(11-44) 
 
Koebl  
(54);1998 
32 ISD 28 1.13 3.9 4 Subj+Obj 59 (19)  41 (13) 0 12 6.25% (2) UTI 
Sheriff 
(53);1997 
34/ 
     7 
     2 
ISD(-/+HU) 
ISD+HU 
Neurop 
sphincter 
34 1.19 5 6 Subj - 
- 
- 
- 
- 
- 
52 (18)  
100 (7) 
0 (2) 
0 24 
3 
All had hematuria, 
dysuria,frequency; 
11.8%  (4) retention 
Harriss 
(52);1996 
40 NS 15 1.25 2-7 10 Subj+Obj 
Subj 
40 (16) 
40 (16) 
33 (13) 
18 (7) 
27 (11) 
42 (17) 
0 3 
36 
All had dysuria; 
7.5% (3) retention 
 
n: Number, GSI: Genuine Stress Incontinence, p: primairy, s: secondary, NS: Not Stated, ISD: Intrinsic Sphincter Deficiency, HU: Hypermobile Urethra, Subj: Subjective, Obj: Objective, UTI: Urinary Tract Infection, 
Neurop: Neuropathic. 
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Abstract 
A study was carried out to evaluate efficacy of Macroplastique® (MPQ) Implantation System 
(MIS), in women with urodynamic stress urinary incontinence (SUI) and urethral 
hypermobility after an unsuccessful conservative treatment. This is a prospective randomized 
controlled trial in women without previous incontinence surgery. Twenty-four women 
received MPQ. Twenty-one controls underwent a pelvic floor muscle exercises home 
program. Follow-up was at 3 months and the MPQ group also at 12 months. At 3 months, pad 
usage decreased significantly more in the MPQ group than in the control group (p=0.015). 
According to physician and patient self-assessment, respectively, 71% and 63% women in the 
MPQ group were considered cured or markedly improved. This was significantly higher 
compared to controls. There was a significant higher increase of Incontinence Quality-of-Life 
questionnaire score in the MPQ group compared to controls (p=0.017). Improvements in 
MPQ group at 3 months are sustained to 12 months. Adverse events were mild and transient. 
MIS is an acceptable option for women with SUI and urethral hypermobility.  
 
Key words: Hypermobility, Macroplastique® Implantation System, Polydimethylsiloxane, 
Quality of life, Randomized clinical trial, Stress urinary incontinence. 
 
Macroplastique® and Macroplastique® Implantation System are trademarks of Uroplasty, 
Geleen, the Netherlands. 
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Introduction  
For the treatment of stress urinary incontinence (SUI) in adult women there is a broad variety 
of therapies nowadays. They range from physiotherapy to surgical interventions. Injection 
therapy with urethral bulking agents is generally considered as a minimally invasive 
procedure for SUI (1). However “minimally invasive” is a relative term and can be viewed as 
minimally invasive from the surgeon’s perspective or the patient’s. Acceptance for injection 
therapy as the least invasive of all surgical procedures is progressing (2,3).  
Injection therapy can be used for all types of SUI. Urethral hypermobility is thought to 
decrease the success of treatment with injectables (4). However, published results of 
periurethral collagen injections for SUI caused by hypermobility indicate positive outcome 
(5). No differences in success rates with and without hypermobility were reported (6). 
Macroplastique® is a urethral bulking agent that has been used in the treatment of urodynamic 
stress incontinence (USI) in adult women for approximately 9 years (2,7,8). In studies success 
rates vary from 58% (long term) to 73% (short term) (9). Macroplastique® is a bulking agent 
that consists of solid polydimethylsiloxane particles with a mean maximum diameter of 209 
µm (10). After injection, these particles seem to be non-migratory and will be organized 
within 6 to 8 weeks in firm nodules with infiltrated collagen and surrounded by a fibrous 
sheath that is well developed at 9 months (11-14). 
The aim of this study is to evaluate the efficacy and the quality of life in women using the 
Macroplastique® Implantation System (MIS), a novel guiding instrument for transurethral 
injection of Macroplastique®, as a minimally invasive procedure in adult women with USI 
and urethral hypermobility after an unsuccessful conservative treatment (i.e., no improvement 
of SUI after pelvic floor muscle exercises (PFME)). 
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Materials and methods  
The study was approved by the Medical Ethical Committee of the University Hospital 
Maastricht, the Netherlands. Data out of this study and the informed consent forms were 
obtained complying with the applicable regulatory requirements, adhering to Good Clinical 
Practice and to the ethical principles that have their origin in the Declaration of Helsinki (15). 
The study is designed to comply with the CONSORT statement and follows the CONSORT 
checklist registration study (www.consort-statement.org). 
Forty-seven adult women with USI and urethral hypermobility after an unsuccessful 
conservative treatment and no history of previous incontinence surgery were included in this 
prospective, randomized controlled and single center clinical trial between April 2002 and 
May 2007. Prior to participation of this study each woman completed dipstick urinalysis, a 
Quality of Life Questionnaire (QoL), Patient Questionnaire including Stamey incontinence 
rating (16). Stamey rating is as follows. Grade 0: The patient is continent (dry). Grade 1: The 
patient will lose urine with sudden increases in abdominal pressure (stressful activities such as 
lifting weights, coughing or sneezing) but never in bed at night. Grade 2: The patient’s 
incontinence worsens with lesser degrees of stress such as walking, standing erect from a 
sitting position or sitting up in bed. Grade 3: The patient has total incontinence and urine is 
lost with any activity, irrespective of position. Also a 
Frequency-volume chart (FVC) and 1-hour International Continence Society pad test (17) in 
addition to routine urogynecological work-up including detailed physical examination with 
assessment of bladder neck excursion measurement and pelvic organ prolapse (18), 
urodynamic assessment were performed. The Incontinence Quality-of-Life (I-QoL) 
Questionnaire was used in this study for the assessment of QoL (19). The Dutch-translated 
and validated version is a reliable instrument for the assessment of QoL in women with 
urinary incontinence. The mean score lies theoretically between 1 and 5 and the higher the 
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score is, the more satisfied patients are about their continence condition. The 22 I-QoL item 
scores can be divided in three domains: “avoidance and limiting behavior”, “psychosocial 
impacts”, and ”social embarrassment”. Measurement of bladder neck mobility was assessed 
by the Q-tip test (20). Independently, Valsalva leak point pressure was measured. This 
measurement provides a validated tool to assess urethral function allowing an estimation of 
the relative contributions of intrinsic sphincter deficiency and urethral hypermobility (21).  
Women, who met the primary inclusion and exclusion criteria (Table 1), were considered 
candidates for randomization. Written informed consent was obtained from all women. The 
women were randomized for Macroplastique® injection utilizing the Macroplastique® 
Implantation Device (MID) or a control PFME home training program.  Randomization 
process was performed using sealed envelopes containing the treatment assignment. A table 
of random numbers was used, all 0-4 were assigned to MPQ and all 5-9 were assigned to 
control PFME home training program.  The control group was offered written instruction 
material for the maintenance of the PFME home training program. 
The transurethral injection was performed using the MIS. The MIS consists of a set of two 
syringes of Macroplastique® (2.5 ml. each), the implantation device (MID) and two special 
needles. The MID is used to standardize the location of periurethral injection, as described by 
Henalla et al (22). The initial injection was placed 10 mm from the bladder neck. The 
procedure was performed under sterile conditions and was carried out under local anesthesia 
in day case setting. Although only women with negative urinalysis and urine culture were 
allowed to undergo the intervention, post-operatively, 250 mg ciproxin twice daily was given 
for 5 days as prophylaxis. If the patient was unable to pass urine spontaneously up to 3 or 4 
hours following the procedure, “in and out catheterization” with a catheter Ch12 was 
performed to relieve any symptoms of urinary retention.  If residuals of more than 100 ml 
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were detected the patient was instructed to perform clean intermittent selfcatheterization 
(CISC) with a catheter Ch12. 
Both patient groups were followed up to 3 months from the moment of injection and the 
Macroplastique® group also up to 12 months after treatment. The 3- and 12-month follow-up 
visit included an FVC, I-QoL Questionnaire, Patient Questionnaire and a pad test. A further 
Macroplastique® implantation procedure was scheduled after the 3-month follow-up, if 
clinically indicated or requested by the patient. A re-implantation was performed at a new 
level, in the mid-urethral position as defined by location with the MID. After repeat 
Macroplastique® implantation, women were again followed up at 3 and 12 months. Objective 
assessments of treatment outcome are the results of pad testing and FVC. Subjective 
assessments of treatment outcome are the results of I-QoL Questionnaire with Stamey 
incontinence rating, side effects and complications, investigator Stamey incontinence rating, 
and subjective investigator stress incontinence cure rating. Treatment success and failure are 
defined as follows: success is “cured” (dry) or “markedly improved” (no further incontinence 
treatment needed), and failure is “slightly improved” (requires further incontinence treatment) 
or “unchanged” (requires further incontinence treatment). 
 
Statistical analysis 
The sample size was determined using the following power calculation. Given p1=30% 
(success rate of control), p2=75% (success rate of Macroplastique), α=0.05, β=0.05, results in 
a value of 25.5 for n. The number of patients of each group should be a least 26. Metric 
variables are first inspected for normality of statistical distribution by the Kolmogorov-
Smirnov test. If normally distributed, means and standard deviations are given for univariate 
variables, if not; medians and ranges are also provided. Categorical data are represented by 
frequencies and percentages (or proportions). Patient demographical characteristics and 
  
  
Page 125 
clinical data are broken down for the randomization arm: Macroplastique® group or control 
group. For normally distributed variables, Student t test is used to verify similarity of means 
for baseline characteristics; for non-normally distributed variables the Mann-Whitney test is 
used. For categorical data, the log-likelihood chi-squared test is applied. For the pad test on 
the data a 10-log transformation is also done to ensure normality of distribution for the 
performance of Student t test. The analysis of I-QOL data is performed at two levels:  first, a 
general total scale is calculated on all 22 items and next the three subscales (the avoidance 
and limiting behavior, psychosocial impacts and social embarrassment items) are constructed.  
To test changes in I-QoL data at 3 months after baseline measurements, repeated-measures 
analysis of variance is done and to control these changes for baseline factors or variables 
repeated-measures analysis of covariance is performed. To control for baseline measurements 
(and other confounding variables or factors) in non-normally distributed changes in outcome 
variables measured at 3 months, a Mann-Whitney test is performed on the Studentized 
residuals of these outcomes found in regression analysis.     
According to intention-to-treat principles in data analysis, missing values are imputed by general 
mean substitution.  A p value of less than 0.05 is considered to be statistically significant.   All data 
were analyzed with SPSS-pc, version 15.0 (23).  
 
Results  
The MPQ group contained 24 women and the control group 21. Two patients had to be 
excluded because they did not fulfill inclusion criteria (one was accidentally included twice 
and one had mainly frequency and urgency complaints). Mean age was 55 years (range 40-
76). Baseline characteristics of both groups were similar as shown in Table 1. The injected 
volume of MPQ was 5 ml in all women. An additional injection of 5 ml MPQ was performed 
in two women after the 3-month follow-up.  The treatment was well tolerated according to the 
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women treated, and considered acceptable and easy to perform by the physician. The 
following adverse events of 26 transurethral Macroplastique® injection using Macroplastique® 
Injection System in 24 women were reported; retention 19 (73.1 %)*, mild pain 2 (7.7 %), 
hematuria 2 (7.7 %), dysuria 12 (46.2 %), leakage implant 2 (7.7 %), infection 0 (0 %). 
Duration of retention (>100 ml) and dyuria complaints were 1-2 days, except in one woman 
with persistent retentions because of a “de novo” prolapse of the anterior vagina wall. The 
women experienced these events as acceptable and mild. Product-related side effects were not 
seen. There were no dropouts at the 3-month follow-up (Figure 1).  
The mean pad test at baseline showed a 19.6-g (median 7.5, range 0-115) and 24.9-g (median 
13.8, range 2-84) urinary loss in the control group and MPQ group, respectively. After 3 
months, the mean pad test showed an 11.9-g (median 4, range 0-66.6) and 15.1-g (median 3, 
range 0-133) urinary loss in the control group and MPQ group, respectively. This 
improvement was not statistically significant between the two groups (p=0.328). 
The mean number of pads used per day at baseline was 2.7 (median 3, range 0-6) and 3.4 
(median 3, range 0-6) in the control group and MPQ group, respectively.  After 3 months, the 
mean number of pads were 2.5 (median 2, range 0-6) and 1.9 (median 1, range 0-11) in the 
control group and MPQ group, respectively. The number of pads used at 3 months in the 
MPQ group decreased statistically significantly compared the number used in the control 
group (p=0.015). 
After the 3-month follow-up, five women in the MPQ group received other continence 
treatment because of treatment failure. The incontinence condition of women was rated by 
Stamey rating. At baseline and 3-month follow-up the frequencies in grading for both groups 
as well as the 12-month follow-up of the MPQ group are shown in Table 3. At 3-month 
follow-up the Stamey grading showed a statistically significant difference compared to 
baseline scores (p=0.020). 
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The physician’s global impression of the incontinence condition of women was rated by the 
final surgeon incontinence rating (Table 4). The number of women (17; 70.8%) that was 
“cured” or “markedly improved” at three months was statistically significantly higher than 
that in the control group (6; 28.5%; p=0.029). 
The subject’s global impression of the incontinence condition was rated by patient self-
assessment of the incontinence problem and is presented in Table 4. There was a statistically 
significant difference in the number of women (15; 62.5%) “cured” or “markedly improved” 
at 3 months in the MPQ group compared to that in the control group (4; 19.0%; p=0.002). 
The Dutch-validated overall 22-item I-QoL showed a mean total score at baseline for the 
control group and MPQ group of 2.96 (SD=0.62) and 2.59 (SD=0.61), respectively, and at 3 
months this mean total score was 3.03 (SD=0.66) and 3.20 (SD=0.73), respectively (Table 
5A). The increase in the MPQ group was significantly higher compared to the control group 
(F ratio=9.83:1 and 43 df, p=0.003). When the I-QoL scores are corrected for baseline values 
the difference remained statistically significant (F ratio=6.15:1 and 42 df, p=0.017). The mean 
scores and standard deviations of the domain scales are also shown in Table 5. In all three 
scales and controlled for their respective baseline measurements, there was a statistically 
significant improvement in the means of the MPQ group compared to the ones of the control 
group (F=4.57:1 and 42 df, p=0.038, F=4.85:1 and 42 df, p=0.033, F=7.99:1 and 42 df, 
p=0.007, respectively). The increase in mean scores was the highest on the “social 
embarrassment” subscale after correction for possible differences in baseline values between 
the control and MPQ group. In contrast to the control group, the I-QoL for the MPQ group 
was again measured at 12 months after treatment. If – outside the trial data analysis – a cohort 
trend analysis for just these 18 patients who had a successful MPQ treatment at 3 months is 
done, the improved mean overall and subscale scores in I-QoL at 3 months turn out to be 
sustained to the 1-year follow-up. The overall score and the subscale score social 
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embarrassment seem even to improve statistically significant compared to the 3-month scores 
(F=4.87:1 and 17 df, p=0.041, F=7.77:1and 17 df, p=0.013, respectively; Table 5).    
At 12 months, physician and patient self-assessment “cure” and “markedly improved” rate 
was 88.9% (16/18) and 82.4% (14/17) in the MPQ group, respectively (Table 4). After 
treatment, five women presented with symptoms of de novo urgency but only one needed 
medical treatment. 
 
Discussion 
To our knowledge, this is the first randomized clinical trial comparing transurethral 
Macroplastique® injection with a control pelvic floor muscle exercises home training program 
in adult women with urodynamic SUI and urethral hypermobility after an unsuccessful 
conservative treatment. The enrollment time was long (5 years); this could be due to the strict 
inclusion and exclusion criteria. Also in this period of time the suburethral slings became 
popular and could have been of influence on the patient’s choice of treatment. 
The exact mechanism of achieving continence with urethral bulking agents is unknown. It is 
commonly thought that they increase urethral resistance at the level of the bladder neck by 
adding “bulk” or provide internal support to the urethral mucosa and creating urethral 
coaptation when injected submucosally (14).  
At 3 months, results of the pad test results showed improvement, although no significant 
difference between the two groups could be shown. We have used the 1-h pad test as 
recommended by the International Continence Society (17). However, a number of studies 
have reported poor reproducibility for the 1- and 24-h pad test (24-27). In a study by Simons 
et al, the test-retest reliability of the 1-h pad test was shown to be inadequate, with the first 
and second tests differing by -44 to +66 g, despite the women having similar bladder volumes 
(27).  Lower anxiety levels at the second test may account for this finding. The 1-h pad test is 
  
Page 129 
a useful baseline measure of incontinence, but the poor repeatability suggests that is not an 
optimal measure of post-treatment.  
More clearly, the decrease in number of pads used in the MPQ group at 3 months was 
significantly different from the control group. Also, the subjective parameters were 
significantly better in the MPQ group compared to the control group. The “cure” and 
“markedly improved” rates were sustained in the MPQ group at 12 months. These results of 
MPQ treatment of SUI in patients with urethral hypermobility are in line with data from 
literature in patients without hypermobility (28). Comparing the results with other more 
invasive surgical treatments the MPQ shows a slightly lower success rate, however with a 
lower risk of complications (29). In this study the retention rate seems rather high. This can be 
explained by strict control of women after the procedure. The duration of retention was 1 to 2 
days and treated by CISC, except in one woman with a body mass index of 40 kg/m², who 
had persistent retention because of a ”de novo” prolapse of the anterior vagina wall unrelated 
to the procedure. Surgical correction of this prolapse was necessary. CISC may influence the 
results of injection therapy by possible dislocation and/or loss of the bulking agent. However, 
a small-sized catheter (Ch 12) was used to minimalize this risk as much as possible. The 
improvement in the quality of life is in the same range as with surgical interventions and 
confirms the trend in patient’s preference to have a procedure with a lower risk of 
complications (30). In a recent study of Robinson et al, the majority of women have realistic 
expectations regarding outcome hoping for improvement so that their quality of life increases. 
In general, they are able to tolerate the inconvenience of minor lower urinary tract symptoms. 
Women would appear to prefer a minor procedure with a lower risk of complications and are 
content to accept a lower success rate (30).  
An advantage of Macroplastique® implantation using the MID is that it is performed 
following an out-patient treatment protocol requiring local anesthesia only. Also, the 
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instrument is easy to handle in comparison to the cystoscope, with predetermined and 
consistent depth of needle penetration, and consistent implant placement at three 
predetermined locations. 
 
Conclusions 
In the treatment algorithm of stress urinary incontinence, the bulking agent Macroplastique® 
using MPQ Implantation Device seems to be a suitable option as a first-line surgical 
treatment. The procedure is easy to perform, safe and well accepted by women and physician. 
The success rates are satisfactory and the patient’s quality of life increases significantly. The 
results appear to be sustained at least for 1 year postoperatively. 
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Table 1. Inclusion and exclusion criteria 
Inclusion 
-Female and at least 18 years of age 
-Urodynamic stress urinary incontinence and urethral hypermobility 
-Urodynamic assessment of SUI and VLPP > 60-cm water 
  
Page 134 
-SUI not shown defined improvement after PFME therapy 
-No more than stage 0, 1 or 2 pelvic organ prolapse (Bump classification) 
-Negative dipstick urinalysis 
-Post-void residual urine ≤100 ml 
-Not pregnant or within 12 months postpartum 
-Understanding of the Dutch language 
-Written informed consent document 
Exclusion 
-Any prior solid particle UBA treatment or any surgical anti-incontinence procedure 
-A form of urinary incontinence other than SUI contributing substantially to their symptoms 
-A neurogenic bladder 
-Urinary incontinence due to an anatomical defect, fibrotic urethral mucosa (preventing 
Macroplastique® bolus formation), tissue damage due to injury, pelvic radiotherapy or other 
therapy affecting the bladder neck and/or urethral tissues 
-A history of intermittent or long-term use of intraurethral continence devices 
-Voiding difficulties 
-A history of unexplained haematuria  
-Cystitis, urethritis or evidence of possible infection, which would preclude safe penetration 
of the urethral wall with the implantation needle 
-An incurable malignant disease or other form of disease that is advancing rapidly and 
causing deterioration of the patient’s physical condition 
-Any condition that could lead to serious postoperative complications (e.g. current infection 
or uncontrolled diabetes) 
-Lactating, within 12 months postpartum or planning to become pregnant in the next 12 
months 
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-Morbidly obese (i.e., Body Mass Index; BMI>40 kg/m²) 
-Unable or unwilling to perform clean intermittent self-catheterization if the need arises (e.g., 
lack of manual dexterity, arthritic hands, dementia, etc.) 
 
Table 2. Patient’s characteristics 
  MPQ group (n=24) Control group (n=21) p value 
  
Mean age, years (SD; range)  54.7 (8.9; 41-76)  55.6 (8.9; 40-73)  0.73 
Mean BMI, kg/m2 (SD; range)                            26.6 (4.3; 20-40)  28.3 (8.3; 19-38)  0.41 
Menstrual cycle (normal/perimeno/meno)  6/3/15   7/2/12   0.81ª 
Parities (median)  2                              2                                        0.23ª  
Duration of incontinence, months (range)  142(36-360)  118(36-360)  0.35 
VLPP, cm water (SD; range)  102(28; 70-172)  93(21; 63-136)  0.28 
SD=standard deviation 
 ª  =log-likelihood chi-squares test (other p values: Student’s t test) 
 
 
Table 3.  Stamey rating frequencies (n) for the control and the MPQ group at baseline 
and at 3-month follow-up and at 12 months for the successful part of the MPQ group 
only 
Grade  0 I II III p value 
Control  (n=21) 0 14 7 0  Baseline 
MPQ  (n=24) 1 15 8 0  
Control  (n=21) 1 16 4 0  3 months 
MPQ   (n=24) 8 15 1 0 0.020 
12 months MPQ  (n=18) 10 7 1 0  
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Table 4.  Final surgeon’s subjective cure rating and the patient self-assessment of 
patient’s incontinence condition (n) for the control and the MPQ group at 3-month 
follow-up and at 12 months for the successful part of the MPQ group only 
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21 2 4 4 11  21 0 4 3 14  
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24 8 9 1 6 0.029 24 7 8 2 7 0.002 
MPQ 
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18 9 7 1 1  17 ª  6 8 2 1  
ª One missing data  
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Table 5.  A] mean (sub)scale scores and standard deviations (sd) of the I-QoL at baseline 
and 3 months for both treatment groups (overall mean imputed data; n=45). Scores will 
lie between 1.00 (worst possible QoL) and 5.00 (best possible QoL).  B] mean (sub)scale 
scores and standard deviations (sd) of the I-Qol at baseline, three and twelve months for 
patients who had a successful MPQ treatment after 3 months (n=18). Scores will lie 
between 1.00 (worst possible QoL) and 5.00 (best possible QoL) 
A 
Subscale treatment n baseline  3 months p value 
 
p value 
controlled for 
baseline values 
control 21 2.96 (0.62) 3.03 (0.66)   
Overall 
MPQ 24 2.59 (0.61) 3.20 (0.73) 0.003ª 0.017 c 
control 21 2.86 (0.72) 2.99 (0.71)   Avoidance & limiting 
behavior MPQ 24 2.55 (0.65) 3.26 (0.86) 0.012ª 0.038 c 
Control 21 3.27 (0.66) 3.31 (0.65)   
Psycho-social impacts 
MPQ 24 2.76 (0.70) 3.37 (0.74) 0.003ª 0.033 c 
control 21 2.53 (0.66) 2.59 (0.87)   
Social embarrassment 
MPQ 24 2.31 (0.68) 2.95 (0.81) 0.004ª 0.007 c 
ª ANOVA results (time * group) effects 
c ANCOVA results (time * group) effects 
 
B 
Subscale n Baseline 3 months 12 months p value p value 
Overall 18 2.58 (0.64) 3.38 (0.70) 3.85 (0.81) 0.041 b 0.006 d 
Avoidance & limiting behavior 18 2.47 (0.58) 3.37 (0.80) 3.65 (0.73) 0.185 b 0.093 d 
Psychosocial impacts 18 2.76 (0.77) 3.60 (0.66) 3.94 (0.78) 0.157 b 0.058 d 
Social embarrassment 18 2.35 (0.71) 3.13 (0.73) 3.77 (0.97) 0.013 b 0.008 d 
b Paired t test 
d Wilcoxon paired test 
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Figure 1.  Flow diagram of study  
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232 women on recruitment list:  
47 selected 
A = 26 women B = 21 women 
baseline treatment 24 baseline home training program   21 
3-month follow-up 24 3-month follow-up   21 
12-month follow-up 18  
  
Page 139 
Chapter 8 
Discussion and conclusions 
This thesis focuses on the efficacy, safety and durability of urethral bulking agents (UBA’s) 
using new techniques of transurethral injection as a minimally invasive procedure in adult 
women with stress urinary incontinence (SUI). Based on these results, the place of these 
techniques in the treatment algorithm of SUI is established.  
SUI in adult women is an important health problem with high impact on Quality of Life 
(QoL) and there is a clear need for treatment (1). The PURE (Prospective Urinary 
Incontinence REsearch) study provides insight into patient characteristics, associated bother 
and treatment patterns of SUI symptoms in clinical practice (2,3). The majority of patients 
(42%) had symptoms of moderate severity, 30% of the patients had severe symptoms and 
17% had very severe symptoms. Quality of life (QoL) decreased with increasing symptom 
severity. Despite the negative impact of SUI on QoL, women often fail or delay seeking 
treatment. This study showed that nearly half of the patients (48%) suffered from their 
symptoms for less than 2 years before consulting a physician; 28% delayed seeking treatment 
for 3-5 years, with 13% waiting for 6-10 years and the remaining 11% waiting for 11 or more 
years. Several reasons may explain this delay, including the misconception that the condition 
is a normal consequence of childbirth and aging, the embarrassment about discussing SUI 
with a physician and the lack of knowledge about available therapy (4,5). Of the incontinent 
women, 20-45% had received conservative treatment (mainly pelvic muscle floor therapy; 
PFMT), 25-41% had received medication, and only 2-4% had undergone surgery. 
An initial conservative approach of pelvic muscle floor therapy (PFMT) in association with 
lifestyle modifications is essential before embarking on more invasive treatment modalities. 
PFMT is considered as better than no treatment by the Cochrane Collaboration and is 
recommended as first-line treatment for SUI by the 3rd  International Consultation on 
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Incontinence (ICI; 6,7). Long-term success of PFMT is much dependent of patient motivation 
and compliance. However, a significant number of patients have persistent symptoms after 
PFMT. PFMT improve the extrinsic supporting mechanism. In cases of a (concurrent) 
dysfunction of the intrinsic urethral closing mechanism, the object of PFMT is to compensate 
this mechanism as far as possible by improving the functionality of the pelvic floor muscles 
(8). So, it is not likely that these patients will recover completely. This patient group would be 
candidate for minor invasive procedures as injection therapy with UBA’s. Also surgical 
intervention can be proposed. The choice between these two treatment options must be made 
on the basis of efficacy, safety (and the efficacy/safety balance), and cost aspects. Surgical 
intervention is widely considered as the most effective option for SUI, although it is not 
suitable for all patients. Injection therapy is generally associated with a lower objective cure 
rate compared to surgery (9). However with reduced invasiveness comes the potential for 
improved tolerability, decreased morbidity and, therefore, similar improvements in overall 
QoL (9). Two studies comparing injection therapy and surgery found superior objective 
efficacy with surgery, but no significant differences in QoL improvements (10,11). In recent 
years several suburethral tapes seem to result in high cure rates (84-95%) that remain stable 
over time, with a reported 85% of patients cured and 11% with significant improvements after 
5 years (12-14). However, the adverse events of tapes are still substantial and can have a 
serious impact on quality of life, as described in chapter one. A survey (2003) of patients with 
SUI showed that most patients prefer less invasive therapy with a lower risk of complications, 
even if the chance of cure may be lower than with major (more invasive) procedures (15). 
Therefore, a focus on patient’s wishes and expectations with respect to success and risks is 
required. From the patient perspective it could be speculated that the lower cure rate may be 
of less importance when weighted against the potential complications (9). With this 
information injection therapy could have an important place in a treatment algorithm of SUI. 
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Many different UBA’s have been used as described in chapter two, although the ideal one 
remains to be discovered. In general, injection therapy was offered to frail elderly women, 
obese individuals, previously operated patients and patients unwilling or unfit to undergo 
more invasive surgery. UBA’s were usually used for intrinsic sphincter deficiency (ISD) 
related SUI, although there is good evidence that women with (concomitant) urethral 
hypermobility respond similarly (16). Nowadays, more and more we are leaving the simple 
concept of a dichotomy between ISD and urethral hypermobility as causes for or associations 
with SUI. In the standardization of terminology report by the ICS (17) and the more recently 
published consultation of the ICI 2004 meeting the description was changed into a variable 
combination of these factors. Long-term outcome studies of correction of hypermobility point 
in the direction that there may be more urethral weakness among patients with urethral 
hypermobility than had been previously considered. Most studies of UBA’s were designed for 
ISD related SUI. If there was concurrent urethral hypermobility this could be a reason for 
exclusion in such a study. The safety and durability of various UBA’s remain a concern (18). 
No differences in UBA’s from an efficacy point of view have been found. Different injection 
techniques of UBA’s, endoscopic and non-endoscopic administration (blind injection using a 
guiding instrument), have been used. The recent development of two devices for blind 
injection has increased the speed and convenience of urethral injection, removing the need for 
surgical facilities (9). The devices are the Implacer® device for blind administration of 
NASHA/Dx copolymer (non-animal stabilized hyaluronic acid/dextranomer; Zuidex™) and 
the Macroplastique® Implantation System (MIS) for blind administration of 
polydimethylsiloxane/silicone microimplants (Macroplastique®).  
Before starting our randomised  clinical trial (RCT) of silicone microimplants 
(Macroplastique®) described in chapter seven, the literature of injection therapy with UBA’s 
for treating SUI in adult women was of rather poor quality, and therefore difficult to compare 
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because of several factors, such as different patient selection, materials, techniques, definition 
of success, number of treatments, and follow-up period.  In chapter six, a systematic review 
about the efficacy of silicone microimplants showed a low methodological quality of included 
studies (19). Therefore, at that time results should be interpreted with caution and no firm 
conclusions about the efficacy of this UBA were possible.  
Injection therapy can achieve significant improvement of symptoms in up to 73% of patients 
with a cure rate of 24-36% in the short term (18). Many short-term studies have been 
performed, although long-term evidence confirming the durability of treatment effects needs 
to be strengthened (9).  In a pilot study (open, prospective, multicenter study) of 42 invasive 
therapy-naive women with stress urinary incontinence (ISD and/or urethral hypermobility) 
treated with NASHA/Dx copolymer using the Implacer™ device, 76% of women showed 
improvement of leakage at 3 and 12 months post treatment (20). Statistically significant 
reductions in median urine leakage and in the median number of incontinence episodes in 24 
hours were observed. Between 12 and 36 months little deterioration in these efficacy 
parameters were observed (21). Significant improvements of QoL measurements were 
observed in 7 of ten King’s Health Questionnaire (KHQ) domains at 12 months, and 6 of ten 
at 36 months (21,22). This study has its limitations, as the primary endpoint, change from 
baseline in cough-induced leak point pressure (CILPP), could not be obtained. CILPP was not 
measured consistently among the centers, values proved difficult to verify, and a large 
number of values were missing. Only a small number (N=17) of women were available at 36 
months. Nevertheless, this study showed statistically significant improvement in subjective 
and objective measurements and sustained for at least 36 months. 
In chapter 7, the first RCT has been described comparing Macroplastique® injection(s) 
utilizing the Macroplastique® Implantation Device with a control pelvic floor muscle 
exercises home training program in adult women with urodynamic SUI and urethral 
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hypermobility after non-successful conservative treatment. All subjective (I-QoL 
Questionnaire with Stamey incontinence rating, investigator Stamey incontinence rating, and 
subjective investigator stress incontinence cure rating) and objective measurements 
(frequency/volume chart and one-hour ICS pad test) showed a more pronounced statistically 
significant improvement in the Macroplastique group. Only the results of the pad test were 
not statistically significant between groups at 3 months, although the pad test showed 
improvement in both groups. The number of women (N=17; 70.8 %) that was cured or 
markedly improved at three months was statistically significantly higher than in the control 
group (N=6; 28.5%). The increase of the overall score and subscale scores of I-Qol in the 
Macroplastique group was significantly higher compared to the control group. The subjective 
and objective improvements in Macroplastique group at 3 months are sustained at 12 months 
(23). The number of participants of this RCT was rather limited (Macroplastique group 
contained 24 women and the control group 21) and the enrolment time was long (5 years). 
This could be due to the strict in- and exclusion criteria of this study and also to the fact that 
in this period of time the suburethral tapes became popular and have influenced the patient’s 
choice of treatment. 
The efficacy and safety of UBA’s depends on the material used, the technique applied and the 
experience of the physician (18). The overall safety of these two UBA’s, NASHA/Dx 
copolymer and silicone microimplants, was acceptable in these studies. There are some safety 
concerns with non-biodegradable agents, such as polydimethylsiloxane/silicone. There are 
reports showing an association between silicone gel-containing breast implants and late-onset 
connective tissue disorders (24-26). However, polydimethylsiloxane is a solid elastomer and 
not a silicone gel. No evidence has been reported that elastomers are associated with 
connective tissue disease (27). Particle migration has been only observed with silicone in dogs 
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(28).  NASHA/Dx copolymer, a biodegradable agent, shows no safety concern up to 7 years 
after treatment of SUI (29).  
The two transurethral injection systems studied, the Zuidex™ system and the 
Macroplastique® Implantation System (MIS), were well tolerated by the female patients 
treated as minimal invasive procedure. NASHA/Dx copolymer was administered under local 
or general anaesthesia and silicone microimplants only under local anaesthesia (20,23). Both 
systems were easy to use by the operator. Adverse events were usually mild and uncommon, 
often self-limiting and easily managed. In one patient a pseudocyst developed after 
NASHA/Dx copolymer injection and could be resolved with simple fluid aspiration (21).  
A cost-effectiveness study was not done. Data on this subject are limited in the literature and 
do not allow a final conclusion (30,31). 
The current data indicate that physicians should look beyond objective efficacy rates when 
considering treatment options for SUI (9). Despite superior cure rates with suburethral tapes, 
women may experience similar subjective benefits after injection therapy vs. surgery. Maybe 
QoL aspects (subjective parameters) are more important than leakage outcomes (objective 
parameters). The choice of therapy needs to take many factors (e.g. personal goals and 
expectations, success rates/complications/procedure of a treatment) into account and should 
involve considered discussion between patient and physician, with a comprehensive review of 
the available treatment options for SUI. 
Our studies with NASHA/Dx copolymer and silicone microimplants make it evident that 
injection therapy can be proposed to any adult women with SUI. However, many clinicians 
would feel uncomfortable administering injection therapy to the very young individuals (18). 
Another possible new indication for injectables is recurrent stress urinary incontinence after 
surgery with any of the new suburethral tapes (32). 
  
Page 145 
Patient’s interest will continue drive us away from surgery into minimally invasive therapies 
to restore functionality to diseased areas of the urologic system. The development of new 
UBA’s is on going and progressing, such as the use of muscle-derived stem cells which may 
lead to sphincter regeneration. Strasser et al (2008) suggested that SUI can be treated 
effectively with autologous myoblasts and fibroblasts injected into the rhabdosphincter and 
urethral submucosa by transurethral ultrasound guidance, respectively. At the moment the 
results seem durable (33,34). However, recently these results have been questioned (35). 
Concerns about the ethical study approval and conduct of this study were observed. The study 
was conducted neither according to Austrian law nor according to the standards of the 
International Conference on Harmonisation of Good Clinical Practice. Therefore, this article 
has been withdrawn by The Lancet (36). In theory, the perfect injectable could be the optimal 
alternative for suburethral tapes. 
 
Conclusions 
According to results of these studies, injection therapy using these new delivery systems with 
NASHA/Dx copolymer (Zuidex™ system) and silicone microimplants (Macroplastique® 
Implantation System; MIS) showed a satisfactory efficacy, a good safety profile, an 
acceptable long term durability, and an improvement of QoL aspects for treating SUI in adult 
women. A possible main advantage of injection therapy is the good risk/benefit ratio. 
Therefore, injection therapy should have a place between pelvic floor muscle therapy and 
(more invasive) surgical interventions in an algorithm for treatment of SUI in adult women.  
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Chapter 9 
Summary 
This thesis focuses on the efficacy, safety, and durability of urethral bulking agents (UBA’s) 
using new techniques of transurethral injection as a minimally invasive procedure to treat 
stress urinary incontinence (SUI) in adult women and to assess its place in a treatment 
algorithm of SUI including quality of life aspects. 
SUI is prevalent in adult women and has a considerable impact on quality of life. However, it 
often remains undiagnosed and therefore untreated. Treatment options for SUI are lifestyle 
modifications (losing weight, quitting smoking, regulating fluid intake), pelvic floor muscle 
training (PFMT), minimally invasive devices, pharmacotherapy, urethral injection and 
surgery. In a treatment algorithm of SUI, PFMT in association with lifestyle modifications is 
the first choice before further interventions for SUI. If PFMT fails or has unsatisfactory result, 
invasive treatment modalities can be proposed. Surgical intervention is widely considered as 
the most effective option for SUI, although it is not suitable for all patients. Another option is 
injection therapy with UBA’s but this is generally associated with a lower objective cure rate 
compared to surgery. Although Quality of life (QoL) improvements are similar for both 
treatments. Most patients with SUI prefer less invasive therapy with a lower risk of 
complications, even if the chance of cure may be lower than with more invasive procedures. 
Therefore, a focus on patient’s wishes and expectations with respect to success and risks is 
required. From the patient perspective it could be speculated that the lower cure rate may be 
of less importance when weighted against the potential complications. With this information 
injection therapy can have an important place in a treatment algorithm of SUI. 
After an introduction in chapter 1, chapter 2 presents a general review of injection therapy 
with different UBA’s for SUI in adult women. Many different UBA’s have been used, 
although the ideal one remains to be discovered. In general, injection therapy was offered to 
  
Page 152 
frail elderly women, obese individuals, previously operated patients and patients unwilling or 
unfit to undergo more invasive surgery. UBA’s were usually used for intrinsic sphincter 
deficiency (ISD) related SUI, although there is good evidence that women with (concomitant) 
urethral hypermobility respond similarly. Nowadays, more and more we are leaving the 
simple concept of a dichotomy between ISD and urethral hypermobility as causes for or 
associations with SUI. The safety and durability of various UBA’s remain a concern. No 
differences in UBA’s from an efficacy point of view have been found. Different injection 
techniques of UBA’s, endoscopic and non-endoscopic administration (blind injection using a 
guiding instrument), have been used. The recent development of two devices for blind 
injection (the Implacer™ and Macroplastique® Implantation Device) has increased the speed 
and convenience of urethral injection, removing the need for surgical facilities. 
Chapter 3, 4 and 5 show the efficacy, safety, durability and QoL data of non-animal stabilized 
hyaluronic acid/dextranomer (NASHA/Dx; Zuidex™) copolymer used for transurethral 
injection with a new guiding instrument (the Implacer™) for stress urinary incontinence (ISD 
and/or urethral hypermobility) in adult women. 76% of forty-two invasive therapy-naive 
women showed improvement of leakage at 3 and 12 months post treatment. Statistically 
significant reductions in median urine leakage and in the median number of incontinence 
episodes in 24 hours were observed. Between 12 and 36 months little deterioration in these 
efficacy parameters were observed. Significant improvements of QoL measurements were 
observed in 7 of ten King’s Health Questionnaire (KHQ) domains at 12 months, and 6 of ten 
at 36 months. This study showed statistically significant improvement in subjective and 
objective measurements and sustained for at least 36 months.  
Before we started with our randomised clinical trial (RCT) of another UBA, silicone 
microimplants (Macroplastique®), we performed a systematic review about the efficacy of 
this UBA for SUI in adult women described in chapter six. Only two RCTs, only published as 
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an abstract, were found. Eleven pre-experimental or observational studies were identified. 
Overall, the methodological quality of included studied was low. The main methodological 
shortcomings of the studies were no random allocation procedure, lack of prestratification on 
prognostic determinants, no blinding, small sample sizes, and lack of proper analysis and 
presentation of results. There was variability in the indication for implantation, implantation 
procedure, rate and volume of silicone microimplants. The use of different outcome measures 
in most of the trials made comparison between studies difficult. Therefore, at that time results 
should be interpreted with caution and no firm conclusions about the efficacy of this UBA 
were possible. Lack of methodological quality still is a general problem in most studies 
investigating effects of UBA’s for SUI in adult women. RCT’s, using valid and reliable 
subjective and objective measurements, are necessary to establish the efficacy of injection 
therapy with UBA’s in treating SUI in adult women. 
In chapter 7 we describe the first RCT comparing Macroplastique® injection(s) utilizing the 
Macroplastique® Implantation Device with a control pelvic floor muscle exercises home 
training program in adult women with urodynamic SUI and urethral hypermobility after non-
successful conservative treatment. All subjective and objective measurements showed a more 
pronounced statistically significant improvement in the Macroplastique group. Only the 
results of the pad test were not statistically significant between groups at 3 months, although 
the pad test showed improvement in both groups. The number of women that was cured or 
markedly improved in the Macroplastique group at three months (N=17; 70.8 %) was 
statistically significantly higher than in the control group (N=6; 28.5%). The increase of the 
overall score and subscale scores of I-Qol in the Macroplastique group was significantly 
higher compared to the control group. The subjective and objective improvements in 
Macroplastique group at 3 months are sustained at 12 months. 
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The overall safety of these two UBA’s, NASHA/Dx copolymer and silicone microimplants, 
was acceptable in these studies. Both systems, the Zuidex™ system and the Macroplastique® 
Implantation System (MIS), were well tolerated by the female patients treated as minimal 
invasive procedure and were easy to use by the operator. NASHA/Dx copolymer was 
administered under local or general anaesthesia and silicone microimplants only under local 
anesthesia. Adverse events were usually mild and uncommon, often self-limiting and easily 
managed. In one patient a pseudocyst developed after NASHA/Dx copolymer injection and 
could be resolved with simple fluid aspiration. 
According to results of these studies, injection therapy using these new delivery systems with 
NASHA/Dx copolymer (Zuidex™ system) and silicone microimplants (Macroplastique® 
Implantation System; MIS) showed a satisfactory efficacy, a good safety profile, an 
acceptable long term durability, and an improvement of QoL aspects for treating SUI in adult 
women. A possible main advantage of injection therapy is the good risk/benefit ratio. 
Therefore, injection therapy should have a place between pelvic floor muscle therapy and 
(more invasive) surgical interventions in an algorithm for treatment of SUI in adult women. 
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Chapter 10 
Nederlandse samenvatting 
Dit proefschrift gaat over de effectiviteit, veiligheid en duurzaamheid van ‘urethral bulking 
agents’ (UBA’s) waarbij nieuwe transurethrale injectietechnieken werden gebruikt als een 
minimaal invasieve procedure voor de behandeling van stress urine incontinentie (SUI) bij 
volwassen vrouwen. Verder werd ook gekeken naar de invloed van deze behandeling op 
‘kwaliteit van leven’ aspecten en wat de plaats van deze behandeling is in het 
behandelalgoritme van SUI. 
SUI komt veel voor bij volwassen vrouwen en heeft een aanzienlijke invloed op de kwaliteit 
van leven. Vaak gaan vrouwen met SUI niet naar de dokter omdat ze het in veel gevallen 
beschouwen als een onontkoombaar element van het ouder worden, omdat ze zich ervoor 
schamen, en/of omdat ze het idee hebben dat het onbehandelbaar is. Een mogelijke 
behandeling blijft hierdoor vaak achterwege. Behandelopties voor SUI zijn aanpassingen van 
de levensstijl (gewichtsreductie, stoppen met roken, gereguleerde vochtiname), 
bekkenbodemspieroefeningen, farmacotherapie, transurethrale injectie, en chirurgie. In het 
behandelalgoritme van SUI zijn bekkenbodemspieroefeningen in combinatie met 
aanpassingen van de levensstijl de eerste keuze. Als bekkenbodemspieroefeningen geen 
succes of onvoldoende resultaat hebben, kunnen invasieve behandelmogelijkheden worden 
voorgesteld. Chirurgie wordt gezien als de meest effectieve behandeling voor SUI, maar is 
niet geschikt voor alle vrouwen. Een andere mogelijkheid is injectietherapie met UBA’s maar 
deze behandeling wordt over het algemeen geassocieerd met een lager objectief 
genezingspercentage in vergelijking met chirurgie. Toch laat de verbetering van ‘kwaliteit van 
leven’ aspecten gelijkwaardige resultaten zien voor beide behandelingen. De meeste vrouwen 
met SUI geven de voorkeur aan een minder invasieve behandeling met een lager risico op 
complicaties, ook al is de kans op genezing lager in vergelijking met meer invasieve 
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behandelingen. Daarom is het belangrijk dat er wordt gekeken naar de wensen en 
verwachtingen van vrouwen ten aanzien van succes- en complicatiepercentages van de 
verschillende behandelmogelijkheden. Het lijkt er op dat vrouwen eerder een behandeling 
accepteren met een lager genezingspercentage en minder complicaties dan het omgekeerde. 
Op basis hiervan kan injectietherapie een belangrijke plaats in het behandelalgoritme van SUI 
innemen. 
Na een introductie in hoofdstuk 1, laat hoofdstuk 2 een algemeen overzicht van 
injectietherapie met verschillende UBA’s voor SUI bij vrouwen zien. Verschillende UBA’s 
zijn al in gebruik zonder dat de ideale UBA reeds geïdentificeerd is. In het algemeen werd 
injectietherapie toegepast bij oudere of obese vrouwen, of bij vrouwen die reeds eerder voor 
SUI geopereerd werden. Andere doelgroepen waren vrouwen die geen chirurgie wilden 
ondergaan of niet gezond genoeg waren voor meer invasieve chirurgie. Verder was 
injectietherapie met UBA’s doorgaans geïndiceerd voor SUI gerelateerd aan intrinsieke 
sphincter deficiëntie (ISD). Uit recentere literatuur blijkt echter dat vrouwen met SUI 
veroorzaakt door een (gelijktijdig) bestaande urethrale hypermobiliteit even goed reageerden. 
Tegenwoordig wordt meer en meer het concept van een dichotomie tussen ISD en urethrale 
hypermobiliteit als oorzaak voor of associaties met SUI verlaten. 
Veiligheid en duurzaamheid van UBA’s blijven een punt van zorg. Tot nu toe is geen verschil 
in effectiviteit tussen de verschillende UBA’s gebleken. Verschillende injectietechnieken van 
UBA’s, endoscopische en niet-endoscopische toediening (blinde injectie met gebruik van een 
speciaal daarvoor ontwikkeld instrument), worden gebruikt. Recent zijn twee apparaten voor 
blinde injectie op de markt gekomen (de Implacer™ en Macroplastique® Implantation 
Device). De procedures met deze apparaten kunnen sneller en makkelijker worden toegepast 
zonder noodzaak van chirurgische faciliteiten.  
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De hoofdstukken 3,4 en 5 geven de resultaten van effectiviteit, veiligheid, duurzaamheid en 
‘kwaliteit van leven’ bij gebruik van ‘non-animal stabilized hyaluronic acid/dextranomer 
(NASHA/Dx; Zuidex™) copolymer’ voor transurethrale injectie gebruikmakend van de 
Implacer™ voor ISD en/of urethrale hypermobiliteit gerelateerde SUI bij volwassen vrouwen. 
76% van de 42 niet eerder invasief behandelde vrouwen laten een verbetering van de 
urinelekkage op 3 en 12 maanden na behandeling zien. Er was een statistisch significante 
reductie van de mediane urinelekkage en het mediane aantal incontinentie episodes per 24 
uur. Er was slechts een kleine vermindering van de effectiviteit tussen 12 en 36 maanden. 
Ook werden statistisch significante verbeteringen van ‘kwaliteit van leven’ metingen in 7 van 
de 10 King’s Health Questionnaire (KHQ) domeinen na 12 maanden, en 6 van de 10 na 36 
maanden gezien. Er was dus sprake van een statistisch significante verbetering van zowel 
subjectieve als objectieve metingen persisterend voor tenminste 36 maanden. 
Voor aanvang met de gerandomiseerde klinische trial (RCT) met betrekking tot 
Macroplastique®, een ander UBA van siliconen elastomeren, werd een systematische review 
over de effectiviteit van deze UBA voor SUI bij vrouwen verricht. Deze review is beschreven 
in hoofdstuk 6. Slechts twee RCT’s, gepubliceerd als abstract, en elf pre-experimentele of 
observationele studies werden gevonden. Over het geheel was de methodologische kwaliteit 
van de geïncludeerde studies laag. De belangrijkste methodologische beperkingen van deze 
studies waren: geen randomisatie procedure, ontoereikende prestratificatie op prognostische 
determinanten, geen blindering, kleine aantallen, en ontoereikende analyse en presentatie van 
resultaten. Verder was sprake van variatie in de indicatie voor implantatie, de implantatie 
procedure en het aantal en volume van siliconen micro-implantaten. Het gebruik van 
verschillende uitkomstmetingen in de meeste van deze studies maken vergelijking tussen de 
studies moeilijk. Ten tijde van publicatie van de review werd geconcludeerd de resultaten met 
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voorzichtigheid te interpreteren en vooralsnog geen harde conclusies te trekken over de 
effectiviteit van deze UBA.  
Überhaupt is de gebrekkige methodologische kwaliteit nog steeds een probleem in de meeste 
studies over effecten van UBA’s voor SUI bij vrouwen. Uit de review bleek de noodzaak voor 
RCT’s, waarbij gebruik wordt gemaakt van valide en betrouwbare subjectieve en objectieve 
metingen, om de effectiviteit van injectietherapie met UBA’s als behandeling van SUI bij 
vrouwen vast te stellen. 
In hoofdstuk 7 wordt een RCT beschreven waarbij voor het eerst een groep vrouwen met 
urodynamische SUI en urethrale hypermobiliteit, na een niet-succesvolle conservatieve 
behandeling behandeld met Macroplastique® injectie(s) gebruikmakend van de 
Macroplastique® Implantation Device, vergeleken wordt met een controlegroep die alleen 
maar bekkenbodemspieroefeningen voor thuis deden. Alle subjectieve en objectieve metingen 
lieten een meer uitgesproken statistisch significante verbetering zien in de Macroplastique 
groep. Alleen de resultaten van de pad test waren niet statistisch significant tussen de twee 
groepen na 3 maanden, terwijl de test wel een significante verbetering in beide groepen liet 
zien. Het aantal vrouwen dat genezen of duidelijke verbeterd was in de Macroplastique groep 
(N=17; 70.8 %) bleek statistisch significant hoger dan in de controlegroep (N=6; 28.5%) na 3 
maanden. De toename van de totaal score en afgeleide scores van de incontinentie-‘kwaliteit 
van leven’ vragen (I-Qol questionnaire) in de Macroplastique groep was significant hoger dan 
in de controlegroep. De subjectieve en objectieve verbeteringen in de Macroplastique groep 
na 3 maanden persisteren ook na 12 maanden. 
Veiligheid van de twee bestudeerde UBA’s, NASHA/Dx copolymer en siliconen micro-
implantaten, was acceptabel. Het Zuidex™ systeem en het Macroplastique® Implantatie 
Systeem werden als minimaal invasieve systemen goed verdragen door de deelnemende 
vrouwen en waren makkelijk te gebruiken door de operateur. NASHA/Dx copolymer werd 
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toegediend onder locale of algemene anesthesie en siliconen micro-implantaten alleen onder 
locale anesthesie. Bijwerkingen waren over het algemeen mild, vaak zelflimiterend en 
makkelijk behandelbaar. Bij één vrouw ontstond een pseudo-cyste na NASHA/Dx copolymer 
injectie. Deze werd eenvoudig behandeld met behulp van vloeistofaspiratie. 
Volgens de resultaten van beide studies laat injectietherapie met de genoemde systemen als 
behandeling voor SUI bij volwassen vrouwen een redelijke effectiviteit, een goed 
veiligheidsprofiel, een acceptabele lange termijn duurzaamheid, en een verbetering in 
‘kwaliteit van leven’ aspecten zien. Een mogelijk belangrijk voordeel van injectietherapie is 
de goede verhouding tussen succes en risico van de behandeling. Daarmee dient 
injectietherapie een plaats te hebben tussen bekkenbodemspieroefeningen en (meer invasieve) 
chirurgische interventies in het behandelalgoritme voor SUI bij volwassen vrouwen. 
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